JPH11500146A - Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類 - Google Patents
Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類Info
- Publication number
- JPH11500146A JPH11500146A JP9515371A JP51537197A JPH11500146A JP H11500146 A JPH11500146 A JP H11500146A JP 9515371 A JP9515371 A JP 9515371A JP 51537197 A JP51537197 A JP 51537197A JP H11500146 A JPH11500146 A JP H11500146A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- alkyl
- group
- furan
- methylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title description 6
- 229940111134 coxibs Drugs 0.000 title description 5
- ARISSSXADTYPHZ-UHFFFAOYSA-N 3-methylsulfonyl-4-phenyl-2h-furan-5-one Chemical class O=C1OCC(S(=O)(=O)C)=C1C1=CC=CC=C1 ARISSSXADTYPHZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 346
- 238000011282 treatment Methods 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 230000001404 mediated effect Effects 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- -1 tri-substituted phenyl Chemical group 0.000 claims description 436
- 229910052739 hydrogen Inorganic materials 0.000 claims description 184
- 239000000203 mixture Substances 0.000 claims description 176
- 239000001257 hydrogen Substances 0.000 claims description 172
- 238000000034 method Methods 0.000 claims description 164
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 137
- 125000005843 halogen group Chemical group 0.000 claims description 134
- 125000001424 substituent group Chemical group 0.000 claims description 128
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 106
- 239000002253 acid Substances 0.000 claims description 77
- 125000004429 atom Chemical group 0.000 claims description 62
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 60
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 56
- 229910052799 carbon Inorganic materials 0.000 claims description 56
- 125000001072 heteroaryl group Chemical class 0.000 claims description 52
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 47
- 125000005842 heteroatom Chemical group 0.000 claims description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 35
- 125000002950 monocyclic group Chemical group 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 31
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 28
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 28
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 28
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- 229910052727 yttrium Inorganic materials 0.000 claims description 27
- PBZHVTZQMBGKMT-UHFFFAOYSA-N 4-phenyl-2h-furan-5-one Chemical compound O=C1OCC=C1C1=CC=CC=C1 PBZHVTZQMBGKMT-UHFFFAOYSA-N 0.000 claims description 24
- 231100000252 nontoxic Toxicity 0.000 claims description 23
- 230000003000 nontoxic effect Effects 0.000 claims description 23
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 15
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 10
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- FZYAFLPJDVKKQI-QGZVFWFLSA-N (5r)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC[C@@]1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 FZYAFLPJDVKKQI-QGZVFWFLSA-N 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- OKKGDLZWFJTBDJ-UHFFFAOYSA-N 3-(3,4-difluorophenoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(F)C(F)=C1 OKKGDLZWFJTBDJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 7
- YGYUCOIQCBPDAY-UHFFFAOYSA-N 4-phenyl-2-(2,2,2-trifluoroethyl)-2h-furan-5-one Chemical compound FC(F)(F)CC1OC(=O)C(C=2C=CC=CC=2)=C1 YGYUCOIQCBPDAY-UHFFFAOYSA-N 0.000 claims description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 6
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- HDKLIZDXVUCLHQ-BQYQJAHWSA-N (3E)-3-nonen-2-one Chemical compound CCCCC\C=C\C(C)=O HDKLIZDXVUCLHQ-BQYQJAHWSA-N 0.000 claims description 5
- MEVQAQCAEVVVBK-UHFFFAOYSA-N 3-(3,4-difluorophenoxy)-5-methoxy-5-methyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(OC)(C)OC(=O)C=1OC1=CC=C(F)C(F)=C1 MEVQAQCAEVVVBK-UHFFFAOYSA-N 0.000 claims description 5
- SBPBUYQZVFIIBK-UHFFFAOYSA-N 3-benzoyl-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1C(=O)C1=CC=CC=C1 SBPBUYQZVFIIBK-UHFFFAOYSA-N 0.000 claims description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- ROCYHXLINRXWJW-UHFFFAOYSA-N 3-(3,5-difluorophenyl)sulfanyl-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1SC1=CC(F)=CC(F)=C1 ROCYHXLINRXWJW-UHFFFAOYSA-N 0.000 claims description 4
- SSUJSRHMLFBGKA-UHFFFAOYSA-N 3-(4-chlorophenoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Cl)C=C1 SSUJSRHMLFBGKA-UHFFFAOYSA-N 0.000 claims description 4
- RFJSWOCVCRPHJX-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-4-phenylsulfanyl-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(COC1=O)=C1SC1=CC=CC=C1 RFJSWOCVCRPHJX-UHFFFAOYSA-N 0.000 claims description 4
- BWWGQVVECVBFOE-UHFFFAOYSA-N 3-anilino-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1NC1=CC=CC=C1 BWWGQVVECVBFOE-UHFFFAOYSA-N 0.000 claims description 4
- RJSHDZXWIHIJBI-UHFFFAOYSA-N 5,5-dimethyl-3-(n-methylanilino)-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=CC=CC=1N(C)C(C(OC1(C)C)=O)=C1C1=CC=C(S(C)(=O)=O)C=C1 RJSHDZXWIHIJBI-UHFFFAOYSA-N 0.000 claims description 4
- ONJHHYBWKLDIFI-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 ONJHHYBWKLDIFI-UHFFFAOYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- WTOORHANEMAYPO-UHFFFAOYSA-N 3-(1-cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C1CC1C(C)OC(C(OC1(C)C)=O)=C1C1=CC=C(S(C)(=O)=O)C=C1 WTOORHANEMAYPO-UHFFFAOYSA-N 0.000 claims description 3
- VGLWOZUXEPKTLV-UHFFFAOYSA-N 3-(2,4-difluorophenoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(F)C=C1F VGLWOZUXEPKTLV-UHFFFAOYSA-N 0.000 claims description 3
- OPUNJHWLVLIRBS-UHFFFAOYSA-N 3-(3,4-difluorobenzoyl)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1C(=O)C1=CC=C(F)C(F)=C1 OPUNJHWLVLIRBS-UHFFFAOYSA-N 0.000 claims description 3
- VRNJUSJNNZDCAE-UHFFFAOYSA-N 3-(5-chloropyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Cl)C=N1 VRNJUSJNNZDCAE-UHFFFAOYSA-N 0.000 claims description 3
- KLKVIJCBPREUPJ-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CCOC1=O KLKVIJCBPREUPJ-UHFFFAOYSA-N 0.000 claims description 3
- XDDRSSXSUAEBSD-UHFFFAOYSA-N 4-phenyl-2-propyl-2H-furan-5-one Chemical compound C1(=CC=CC=C1)C=1C(OC(C1)CCC)=O XDDRSSXSUAEBSD-UHFFFAOYSA-N 0.000 claims description 3
- QZBCQQRCXKYILS-UHFFFAOYSA-N 5,5-dimethyl-3-(6-methylpyridin-2-yl)oxy-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1=CC=CC(OC=2C(OC(C)(C)C=2C=2C=CC(=CC=2)S(C)(=O)=O)=O)=N1 QZBCQQRCXKYILS-UHFFFAOYSA-N 0.000 claims description 3
- BXKQWMSQWNZDTH-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-pyridin-2-yloxyfuran-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=CC=N1 BXKQWMSQWNZDTH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 3
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- MEZLBLOYRFMPAC-UHFFFAOYSA-N 2-(3,4-difluorophenoxy)-3-(4-methylsulfonylphenyl)cyclopent-2-en-1-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(CCC1=O)=C1OC1=CC=C(F)C(F)=C1 MEZLBLOYRFMPAC-UHFFFAOYSA-N 0.000 claims description 2
- PUYCKSKASYLLIW-UHFFFAOYSA-N 3-(3,3-dimethylcyclopentyl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C1C(C)(C)CCC1OC(C(OC1(C)C)=O)=C1C1=CC=C(S(C)(=O)=O)C=C1 PUYCKSKASYLLIW-UHFFFAOYSA-N 0.000 claims description 2
- DESBNISDYNFRCI-UHFFFAOYSA-N 3-(3,5-dichloropyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=NC=C(Cl)C=C1Cl DESBNISDYNFRCI-UHFFFAOYSA-N 0.000 claims description 2
- UZSAUWDQSVERKI-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-4-propan-2-yloxy-2h-furan-5-one Chemical compound C1OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 UZSAUWDQSVERKI-UHFFFAOYSA-N 0.000 claims description 2
- XCNHDBDVIVAJHX-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Br)C=N1 XCNHDBDVIVAJHX-UHFFFAOYSA-N 0.000 claims description 2
- AFFHKECMMQJKLB-UHFFFAOYSA-N 3-(diethylamino)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(N(CC)CC)=C1C1=CC=C(S(C)(=O)=O)C=C1 AFFHKECMMQJKLB-UHFFFAOYSA-N 0.000 claims description 2
- GGPKVHLOTGDVJV-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-3-phenylsulfanyl-1-oxaspiro[4.4]non-3-en-2-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(C1(CCCC1)OC1=O)=C1SC1=CC=CC=C1 GGPKVHLOTGDVJV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- LFRQDTGNFOZLCA-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-pentan-3-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC(CC)CC)=C1C1=CC=C(S(C)(=O)=O)C=C1 LFRQDTGNFOZLCA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 2
- PQYQDILXYJVMIB-UHFFFAOYSA-N 3-(5-chloropyridin-3-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CN=CC(Cl)=C1 PQYQDILXYJVMIB-UHFFFAOYSA-N 0.000 claims 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 2
- VHRGUJICHLPTDW-UHFFFAOYSA-N 2-phenylcyclopent-2-en-1-one Chemical compound O=C1CCC=C1C1=CC=CC=C1 VHRGUJICHLPTDW-UHFFFAOYSA-N 0.000 claims 1
- GJJZKGZYUTXFMK-UHFFFAOYSA-N 3-(1-benzothiophen-5-yloxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(OC=2C=C3C=CSC3=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 GJJZKGZYUTXFMK-UHFFFAOYSA-N 0.000 claims 1
- YCLVAHIPNWOMDV-UHFFFAOYSA-N 3-(2,2-dimethylpropoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(OCC(C)(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 YCLVAHIPNWOMDV-UHFFFAOYSA-N 0.000 claims 1
- NSOLEUGGZJTHNS-UHFFFAOYSA-N 3-(3-fluorophenoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=CC(F)=C1 NSOLEUGGZJTHNS-UHFFFAOYSA-N 0.000 claims 1
- FQHQBFIVQROQKA-UHFFFAOYSA-N 3-(6-aminopyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=CC(N)=N1 FQHQBFIVQROQKA-UHFFFAOYSA-N 0.000 claims 1
- FZIZEPNKLINHJQ-UHFFFAOYSA-N 3-(6-chloropyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=CC(Cl)=N1 FZIZEPNKLINHJQ-UHFFFAOYSA-N 0.000 claims 1
- HSNXDRXMMFAZGU-UHFFFAOYSA-N 3-(6-chloropyridin-3-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Cl)N=C1 HSNXDRXMMFAZGU-UHFFFAOYSA-N 0.000 claims 1
- MQGIBKPZEILKCA-UHFFFAOYSA-N 4-(5-isoquinolin-1-yloxy-3,3-dimethyl-4-methylsulfonylcyclohexa-1,5-dien-1-yl)-2h-furan-5-one Chemical compound C1=C(OC=2C3=CC=CC=C3C=CN=2)C(S(C)(=O)=O)C(C)(C)C=C1C1=CCOC1=O MQGIBKPZEILKCA-UHFFFAOYSA-N 0.000 claims 1
- HIUVVOXSYZYIBH-UHFFFAOYSA-N 5,5-dimethyl-3-(2-methylpropoxy)-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(OCC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 HIUVVOXSYZYIBH-UHFFFAOYSA-N 0.000 claims 1
- HJZXSUAVCFVGNB-UHFFFAOYSA-N 5,5-dimethyl-3-(6-methylpyridin-3-yl)oxy-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C1=NC(C)=CC=C1OC(C(OC1(C)C)=O)=C1C1=CC=C(S(C)(=O)=O)C=C1 HJZXSUAVCFVGNB-UHFFFAOYSA-N 0.000 claims 1
- YMECDTRUPBWAKF-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-(1,3-thiazol-2-ylsulfanyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1SC1=NC=CS1 YMECDTRUPBWAKF-UHFFFAOYSA-N 0.000 claims 1
- BKAIDULGUXNMAB-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-quinolin-2-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC=2N=C3C=CC=CC3=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 BKAIDULGUXNMAB-UHFFFAOYSA-N 0.000 claims 1
- MGPCJDUYMCTDRP-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-quinolin-6-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC=2C=C3C=CC=NC3=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 MGPCJDUYMCTDRP-UHFFFAOYSA-N 0.000 claims 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 238000007142 ring opening reaction Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract description 29
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 228
- 238000005481 NMR spectroscopy Methods 0.000 description 146
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 132
- 239000002904 solvent Substances 0.000 description 112
- 235000019439 ethyl acetate Nutrition 0.000 description 101
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 97
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 91
- 239000000243 solution Substances 0.000 description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 239000000460 chlorine Substances 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 55
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 53
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 239000002585 base Substances 0.000 description 40
- 150000002596 lactones Chemical class 0.000 description 37
- 239000012044 organic layer Substances 0.000 description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 35
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 34
- 239000012267 brine Substances 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 239000007787 solid Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- 239000003153 chemical reaction reagent Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 238000003756 stirring Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 239000000284 extract Substances 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 150000002148 esters Chemical class 0.000 description 21
- 239000000725 suspension Substances 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 229940114079 arachidonic acid Drugs 0.000 description 17
- 235000021342 arachidonic acid Nutrition 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 16
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 239000012981 Hank's balanced salt solution Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000002576 ketones Chemical class 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 150000004820 halides Chemical class 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012038 nucleophile Substances 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 7
- 239000012954 diazonium Substances 0.000 description 7
- 150000001989 diazonium salts Chemical class 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 150000003457 sulfones Chemical class 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- SOQVBDSJEUFZMY-UHFFFAOYSA-N 2-(1-cyclopropylethoxy)acetic acid Chemical compound OC(=O)COC(C)C1CC1 SOQVBDSJEUFZMY-UHFFFAOYSA-N 0.000 description 5
- TXHHUINCRBZJDL-UHFFFAOYSA-N 2-(3,4-difluorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(F)C(F)=C1 TXHHUINCRBZJDL-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- YEUYZNNBXLMFCW-UHFFFAOYSA-N 1-bromo-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(Br)C=C1 YEUYZNNBXLMFCW-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000012895 Gastric disease Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001242 acetic acid derivatives Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical class BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940106681 chloroacetic acid Drugs 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- XEBCWEDRGPSHQH-UHFFFAOYSA-N diisopropyl tartrate Chemical compound CC(C)OC(=O)C(O)C(O)C(=O)OC(C)C XEBCWEDRGPSHQH-UHFFFAOYSA-N 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 3
- ZBIULCVFFJJYTN-UHFFFAOYSA-N 2-(4-fluorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(F)C=C1 ZBIULCVFFJJYTN-UHFFFAOYSA-N 0.000 description 3
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229910004713 HPF6 Inorganic materials 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 3
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical compound CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 125000005594 diketone group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940109738 hematin Drugs 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910003002 lithium salt Inorganic materials 0.000 description 3
- 159000000002 lithium salts Chemical class 0.000 description 3
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
- ASAXRKSDVDALDT-UHFFFAOYSA-N propan-2-yl 2,2,2-trifluoroacetate Chemical compound CC(C)OC(=O)C(F)(F)F ASAXRKSDVDALDT-UHFFFAOYSA-N 0.000 description 3
- 229940127293 prostanoid Drugs 0.000 description 3
- 150000003814 prostanoids Chemical class 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- OMMITWGGPIYPLG-UHFFFAOYSA-N 2-(3-chloro-4-methoxyphenoxy)acetic acid Chemical compound COC1=CC=C(OCC(O)=O)C=C1Cl OMMITWGGPIYPLG-UHFFFAOYSA-N 0.000 description 2
- SZEBGAQWWSUOHT-UHFFFAOYSA-N 2-(4-bromophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Br)C=C1 SZEBGAQWWSUOHT-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- GOLVMRZULJWHGT-UHFFFAOYSA-N 2-cyclohexyloxyacetic acid Chemical compound OC(=O)COC1CCCCC1 GOLVMRZULJWHGT-UHFFFAOYSA-N 0.000 description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 2
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical class [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 2
- IXOFPUCWZCAFJX-UHFFFAOYSA-N 2-phenylethanethioic s-acid Chemical compound SC(=O)CC1=CC=CC=C1 IXOFPUCWZCAFJX-UHFFFAOYSA-N 0.000 description 2
- HFLBVHGFPPEJBA-UHFFFAOYSA-N 3-(4-methylsulfonylphenyl)-2-phenoxycyclopent-2-en-1-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(CCC1=O)=C1OC1=CC=CC=C1 HFLBVHGFPPEJBA-UHFFFAOYSA-N 0.000 description 2
- MVKDNXIKAWKCCS-UHFFFAOYSA-N 3-methyl-1h-pyridin-2-one Chemical compound CC1=CC=CN=C1O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- IRWRIGHYGSXWOL-UHFFFAOYSA-N 4,4,4-trifluoro-1-phenylbutan-1-one Chemical compound FC(F)(F)CCC(=O)C1=CC=CC=C1 IRWRIGHYGSXWOL-UHFFFAOYSA-N 0.000 description 2
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- QRVYABWJVXXOTN-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(C=O)C=C1 QRVYABWJVXXOTN-UHFFFAOYSA-N 0.000 description 2
- VCWXQUZQVNKWHF-UHFFFAOYSA-N 4-propoxy-2h-furan-5-one Chemical compound CCCOC1=CCOC1=O VCWXQUZQVNKWHF-UHFFFAOYSA-N 0.000 description 2
- OEUFTIBZEDUUCK-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-phenoxyfuran-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=CC=C1 OEUFTIBZEDUUCK-UHFFFAOYSA-N 0.000 description 2
- SOHMZGMHXUQHGE-UHFFFAOYSA-N 5-methyl-1h-pyridin-2-one Chemical compound CC1=CC=C(O)N=C1 SOHMZGMHXUQHGE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- STNJBCKSHOAVAJ-UHFFFAOYSA-N Methacrolein Chemical compound CC(=C)C=O STNJBCKSHOAVAJ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- NPKSPKHJBVJUKB-UHFFFAOYSA-N N-phenylglycine Chemical compound OC(=O)CNC1=CC=CC=C1 NPKSPKHJBVJUKB-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000004020 Oxygenases Human genes 0.000 description 2
- 108090000417 Oxygenases Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940125890 compound Ia Drugs 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- QBYBLPLPVPUIMD-UHFFFAOYSA-N ethyl 2-(3-chloro-4-methoxyphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(OC)C(Cl)=C1 QBYBLPLPVPUIMD-UHFFFAOYSA-N 0.000 description 2
- PBQNKBWWOXOAOE-UHFFFAOYSA-N ethyl 2-(4-hydroxyphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(O)C=C1 PBQNKBWWOXOAOE-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 150000005748 halopyridines Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- SVOOVMQUISJERI-UHFFFAOYSA-K rhodium(3+);triacetate Chemical compound [Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O SVOOVMQUISJERI-UHFFFAOYSA-K 0.000 description 2
- NMAOJFAMEOVURT-RTKIROINSA-N rosaprostol Chemical compound CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC(O)=O NMAOJFAMEOVURT-RTKIROINSA-N 0.000 description 2
- 229950003055 rosaprostol Drugs 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical group CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- NDLIRBZKZSDGSO-UHFFFAOYSA-N tosyl azide Chemical compound CC1=CC=C(S(=O)(=O)[N-][N+]#N)C=C1 NDLIRBZKZSDGSO-UHFFFAOYSA-N 0.000 description 2
- 229940124279 traditional non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- JTMYHMVWKPSXNE-UHFFFAOYSA-N (1-hydroxycyclopentyl)-(4-methylsulfanylphenyl)methanone Chemical compound C1=CC(SC)=CC=C1C(=O)C1(O)CCCC1 JTMYHMVWKPSXNE-UHFFFAOYSA-N 0.000 description 1
- QZDHVCORNRNWSG-UHFFFAOYSA-N (1-hydroxycyclopentyl)-(4-methylthiophen-2-yl)methanone Chemical compound CC1=CSC(C(=O)C2(O)CCCC2)=C1 QZDHVCORNRNWSG-UHFFFAOYSA-N 0.000 description 1
- RCMQSRMPSWHGKR-AGIABQAESA-N (1r,2s)-1-(1-ethoxyethoxy)-2-methyl-1-(4-methylsulfonylphenyl)butan-2-ol Chemical compound CCOC(C)O[C@@H]([C@@](C)(O)CC)C1=CC=C(S(C)(=O)=O)C=C1 RCMQSRMPSWHGKR-AGIABQAESA-N 0.000 description 1
- OTKVWKMJXKUIFB-NSHDSACASA-N (1s)-2-methyl-1-(4-methylsulfonylphenyl)prop-2-en-1-ol Chemical compound CC(=C)[C@H](O)C1=CC=C(S(C)(=O)=O)C=C1 OTKVWKMJXKUIFB-NSHDSACASA-N 0.000 description 1
- KLLYGDXCCNXESW-UHFFFAOYSA-N (2-fluoroacetyl) 2-fluoroacetate Chemical compound FCC(=O)OC(=O)CF KLLYGDXCCNXESW-UHFFFAOYSA-N 0.000 description 1
- LEWYZEQNYWGOBF-FSPLSTOPSA-N (2s,5s)-2-tert-butyl-5-methyl-1,3-dioxolan-4-one Chemical compound C[C@@H]1O[C@H](C(C)(C)C)OC1=O LEWYZEQNYWGOBF-FSPLSTOPSA-N 0.000 description 1
- KISYRVKLJQJQEB-LJQANCHMSA-N (5r)-3-(5-bromopyridin-2-yl)oxy-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound O([C@](C=1C=2C=CC(=CC=2)S(C)(=O)=O)(C)CC)C(=O)C=1OC1=CC=C(Br)C=N1 KISYRVKLJQJQEB-LJQANCHMSA-N 0.000 description 1
- UNYODXILNOHQKG-GOSISDBHSA-N (5r)-3-(5-bromopyridin-2-yl)oxy-5-methyl-4-(4-methylsulfonylphenyl)-5-(2,2,2-trifluoroethyl)furan-2-one Chemical compound O([C@@](C=1C=2C=CC(=CC=2)S(C)(=O)=O)(CC(F)(F)F)C)C(=O)C=1OC1=CC=C(Br)C=N1 UNYODXILNOHQKG-GOSISDBHSA-N 0.000 description 1
- IXYKLQWDTIGNBA-UHFFFAOYSA-N (6-methoxypyridin-3-yl) acetate Chemical compound COC1=CC=C(OC(C)=O)C=N1 IXYKLQWDTIGNBA-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- RKOUFQLNMRAACI-UHFFFAOYSA-N 1,1,1-trifluoro-2-iodoethane Chemical compound FC(F)(F)CI RKOUFQLNMRAACI-UHFFFAOYSA-N 0.000 description 1
- FHUDAMLDXFJHJE-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-one Chemical compound CC(=O)C(F)(F)F FHUDAMLDXFJHJE-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical group C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- ORIIXCOYEOIFSN-UHFFFAOYSA-N 1,3-benzothiazol-6-ol Chemical compound OC1=CC=C2N=CSC2=C1 ORIIXCOYEOIFSN-UHFFFAOYSA-N 0.000 description 1
- YFVKHKCZBSGZPE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one Chemical compound CCCNC(C)C(=O)C1=CC=C2OCOC2=C1 YFVKHKCZBSGZPE-UHFFFAOYSA-N 0.000 description 1
- FTJGECIARDVRJC-UHFFFAOYSA-N 1-(4-methylsulfanylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(SC)C=C1 FTJGECIARDVRJC-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- CCSUVDYTBGWFIB-UHFFFAOYSA-N 1-benzothiophen-5-ol Chemical compound OC1=CC=C2SC=CC2=C1 CCSUVDYTBGWFIB-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- CJTZXIJETZZARD-UHFFFAOYSA-N 1-iodo-2,2-dimethylpropane Chemical compound CC(C)(C)CI CJTZXIJETZZARD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CJAOGUFAAWZWNI-UHFFFAOYSA-N 1-n,1-n,4-n,4-n-tetramethylbenzene-1,4-diamine Chemical compound CN(C)C1=CC=C(N(C)C)C=C1 CJAOGUFAAWZWNI-UHFFFAOYSA-N 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- IAJINJSFYTZPEJ-UHFFFAOYSA-N 1h-pyrimidin-3-ium-2-one;chloride Chemical compound Cl.O=C1N=CC=CN1 IAJINJSFYTZPEJ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- NVWVWEWVLBKPSM-UHFFFAOYSA-N 2,4-difluorophenol Chemical compound OC1=CC=C(F)C=C1F NVWVWEWVLBKPSM-UHFFFAOYSA-N 0.000 description 1
- GPNYJXANBXUOLW-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-1-yloxy)acetic acid Chemical compound C1=CC=C2C(OCC(=O)O)CCC2=C1 GPNYJXANBXUOLW-UHFFFAOYSA-N 0.000 description 1
- IROWKZOUSZVFER-UHFFFAOYSA-N 2-(3,5-difluorophenyl)ethanethioic s-acid Chemical compound OC(=S)CC1=CC(F)=CC(F)=C1 IROWKZOUSZVFER-UHFFFAOYSA-N 0.000 description 1
- IWSVLBKHBJGMAA-UHFFFAOYSA-M 2-(3-benzyl-4-methyl-1,3-thiazol-3-ium-5-yl)ethanol;chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CC=CC=C1 IWSVLBKHBJGMAA-UHFFFAOYSA-M 0.000 description 1
- DMYZZZCPJOWSNT-UHFFFAOYSA-N 2-(3-fluorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=CC(F)=C1 DMYZZZCPJOWSNT-UHFFFAOYSA-N 0.000 description 1
- FBGYNJKXMKWETB-UHFFFAOYSA-N 2-(4-chloro-3-methylphenoxy)acetic acid Chemical compound CC1=CC(OCC(O)=O)=CC=C1Cl FBGYNJKXMKWETB-UHFFFAOYSA-N 0.000 description 1
- KEYOKPQFLGLSCR-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanethioic s-acid Chemical compound OC(=S)CC1=CC=C(F)C=C1 KEYOKPQFLGLSCR-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- MLXDUYUQINCFFV-UHFFFAOYSA-N 2-acetyloxyacetic acid Chemical compound CC(=O)OCC(O)=O MLXDUYUQINCFFV-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- DCBXZIWICBQPDL-UHFFFAOYSA-N 2-bromo-1-(4-methylsulfonylphenyl)propan-1-one Chemical compound CC(Br)C(=O)C1=CC=C(S(C)(=O)=O)C=C1 DCBXZIWICBQPDL-UHFFFAOYSA-N 0.000 description 1
- XYJYOXRPGNOGEP-UHFFFAOYSA-N 2-bromo-2-methyl-1-(4-methylsulfonylphenyl)propan-1-one Chemical compound CC(C)(Br)C(=O)C1=CC=C(S(C)(=O)=O)C=C1 XYJYOXRPGNOGEP-UHFFFAOYSA-N 0.000 description 1
- WPGLAMIWJZZFHH-UHFFFAOYSA-N 2-bromo-2-phenoxyacetic acid Chemical compound OC(=O)C(Br)OC1=CC=CC=C1 WPGLAMIWJZZFHH-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- HWZUMEVIIGNXGM-UHFFFAOYSA-N 2-chloro-4-methyl-5-nitropyridine Chemical compound CC1=CC(Cl)=NC=C1[N+]([O-])=O HWZUMEVIIGNXGM-UHFFFAOYSA-N 0.000 description 1
- KEOSJDSSBULZBQ-UHFFFAOYSA-N 2-cyclobutyloxyacetic acid Chemical compound OC(=O)COC1CCC1 KEOSJDSSBULZBQ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical class CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- HEXSLVTZXWZKHY-UHFFFAOYSA-N 2-fluoro-2-phenoxyacetic acid Chemical compound OC(=O)C(F)OC1=CC=CC=C1 HEXSLVTZXWZKHY-UHFFFAOYSA-N 0.000 description 1
- RCHVDUSMVBWVNY-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-(4-methylsulfanylphenyl)propan-1-one Chemical compound CSC1=CC=C(C(=O)C(C)(C)O)C=C1 RCHVDUSMVBWVNY-UHFFFAOYSA-N 0.000 description 1
- UXGJQQXURDIXEB-UHFFFAOYSA-N 2-hydroxy-2-methyl-1-(4-methylsulfonylphenyl)propan-1-one Chemical compound CC(C)(O)C(=O)C1=CC=C(S(C)(=O)=O)C=C1 UXGJQQXURDIXEB-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- IQRUSQUYPCHEKN-UHFFFAOYSA-N 2-iodobutane Chemical compound CCC(C)I IQRUSQUYPCHEKN-UHFFFAOYSA-N 0.000 description 1
- HBLJXFWOBRYJMT-UHFFFAOYSA-N 2-methyl-1-(4-methylsulfanylphenyl)pentan-1-one Chemical compound CCCC(C)C(=O)C1=CC=C(SC)C=C1 HBLJXFWOBRYJMT-UHFFFAOYSA-N 0.000 description 1
- OTKVWKMJXKUIFB-UHFFFAOYSA-N 2-methyl-1-(4-methylsulfonylphenyl)prop-2-en-1-ol Chemical compound CC(=C)C(O)C1=CC=C(S(C)(=O)=O)C=C1 OTKVWKMJXKUIFB-UHFFFAOYSA-N 0.000 description 1
- MFIQXAVMTLKUJR-UHFFFAOYSA-N 2-methylpentanoyl chloride Chemical compound CCCC(C)C(Cl)=O MFIQXAVMTLKUJR-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- JWSLLZBWSRRXGC-UHFFFAOYSA-N 2-phenyl-2-propan-2-yloxyacetic acid Chemical compound CC(C)OC(C(O)=O)C1=CC=CC=C1 JWSLLZBWSRRXGC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GYPOFOQUZZUVQL-UHFFFAOYSA-N 2h-isoquinolin-3-one Chemical compound C1=CC=C2C=NC(O)=CC2=C1 GYPOFOQUZZUVQL-UHFFFAOYSA-N 0.000 description 1
- BUOHYNZXWKXACO-UHFFFAOYSA-N 3,3,3-trifluoro-2-methyl-2-trimethylsilyloxypropanenitrile Chemical compound N#CC(C(F)(F)F)(C)O[Si](C)(C)C BUOHYNZXWKXACO-UHFFFAOYSA-N 0.000 description 1
- QKFKROULLRFXMV-UHFFFAOYSA-N 3,3-dimethylcyclopentan-1-ol Chemical compound CC1(C)CCC(O)C1 QKFKROULLRFXMV-UHFFFAOYSA-N 0.000 description 1
- SNYRXHULAWEECU-UHFFFAOYSA-N 3,4-dichlorophenoxyacetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C(Cl)=C1 SNYRXHULAWEECU-UHFFFAOYSA-N 0.000 description 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 1
- BNPWVUJOPCGHIK-UHFFFAOYSA-N 3,4-difluorophenol Chemical compound OC1=CC=C(F)C(F)=C1 BNPWVUJOPCGHIK-UHFFFAOYSA-N 0.000 description 1
- ZICOPWJJZSJEDL-UHFFFAOYSA-N 3,5-dichloro-1h-pyridin-2-one Chemical compound OC1=NC=C(Cl)C=C1Cl ZICOPWJJZSJEDL-UHFFFAOYSA-N 0.000 description 1
- LFYVNHDFVIPZHV-UHFFFAOYSA-N 3,5-difluorobenzenethiol Chemical compound FC1=CC(F)=CC(S)=C1 LFYVNHDFVIPZHV-UHFFFAOYSA-N 0.000 description 1
- KSLLHNGAEZZBKW-UHFFFAOYSA-N 3-(1,3-benzothiazol-6-yloxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(OC=2C=C3SC=NC3=CC=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 KSLLHNGAEZZBKW-UHFFFAOYSA-N 0.000 description 1
- PZOMJAGQUNQIHB-UHFFFAOYSA-N 3-(2,3-dihydro-1h-inden-1-yloxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound CC1(C)OC(=O)C(OC2C3=CC=CC=C3CC2)=C1C1=CC=C(S(C)(=O)=O)C=C1 PZOMJAGQUNQIHB-UHFFFAOYSA-N 0.000 description 1
- MHHIVNMYQIEWDK-UHFFFAOYSA-N 3-(3,4-dichlorophenoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Cl)C(Cl)=C1 MHHIVNMYQIEWDK-UHFFFAOYSA-N 0.000 description 1
- NCQXDPFJWCBCEZ-UHFFFAOYSA-N 3-(4-bromophenoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Br)C=C1 NCQXDPFJWCBCEZ-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- KAGDRELXVLNWDO-UHFFFAOYSA-N 3-(4-fluorophenyl)propanoyl chloride Chemical compound FC1=CC=C(CCC(Cl)=O)C=C1 KAGDRELXVLNWDO-UHFFFAOYSA-N 0.000 description 1
- BYTWQLNHRQIQEQ-UHFFFAOYSA-N 3-(4-methylsulfanylphenyl)-2-phenoxycyclopent-2-en-1-one Chemical compound C1=CC(SC)=CC=C1C(CCC1=O)=C1OC1=CC=CC=C1 BYTWQLNHRQIQEQ-UHFFFAOYSA-N 0.000 description 1
- BFCUKEDGICMBOJ-UHFFFAOYSA-N 3-(5-fluoropyridin-3-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CN=CC(F)=C1 BFCUKEDGICMBOJ-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- IUPMBEGMKVHDEZ-UHFFFAOYSA-N 3-[(3,4-difluorophenyl)-hydroxymethyl]-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1C(O)C1=CC=C(F)C(F)=C1 IUPMBEGMKVHDEZ-UHFFFAOYSA-N 0.000 description 1
- CMXGNFNTQWOTRG-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1CC1=CC=C(F)C=C1 CMXGNFNTQWOTRG-UHFFFAOYSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- JAOQCJLZICQIRI-UHFFFAOYSA-N 3-[hydroxy(phenyl)methyl]-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1C(O)C1=CC=CC=C1 JAOQCJLZICQIRI-UHFFFAOYSA-N 0.000 description 1
- QBLWJJYEVNVEIT-UHFFFAOYSA-N 3-benzyl-5,5-dimethyl-4-(4-methylsulfanylphenyl)furan-2-one Chemical compound C1=CC(SC)=CC=C1C(C(OC1=O)(C)C)=C1CC1=CC=CC=C1 QBLWJJYEVNVEIT-UHFFFAOYSA-N 0.000 description 1
- KNHHNILXEQGEIW-UHFFFAOYSA-N 3-benzyl-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1CC1=CC=CC=C1 KNHHNILXEQGEIW-UHFFFAOYSA-N 0.000 description 1
- ZQXLIXHVJVAPLW-UHFFFAOYSA-N 3-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C(Cl)=C1 ZQXLIXHVJVAPLW-UHFFFAOYSA-N 0.000 description 1
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical compound OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OCVLSHAVSIYKLI-UHFFFAOYSA-N 3h-1,3-thiazole-2-thione Chemical compound SC1=NC=CS1 OCVLSHAVSIYKLI-UHFFFAOYSA-N 0.000 description 1
- VCKWPLYOFMMRDJ-UHFFFAOYSA-N 4,4,4-trifluoro-2-methyl-1-(4-methylsulfanylphenyl)butan-1-one Chemical compound CSC1=CC=C(C(=O)C(C)CC(F)(F)F)C=C1 VCKWPLYOFMMRDJ-UHFFFAOYSA-N 0.000 description 1
- KJGTUKSHPIVAPB-UHFFFAOYSA-N 4,4,4-trifluoro-2-methylbutanoyl chloride Chemical compound ClC(=O)C(C)CC(F)(F)F KJGTUKSHPIVAPB-UHFFFAOYSA-N 0.000 description 1
- SCJCDNUXDWFVFI-UHFFFAOYSA-N 4,4,4-trifluorobutanal Chemical compound FC(F)(F)CCC=O SCJCDNUXDWFVFI-UHFFFAOYSA-N 0.000 description 1
- GIYARLYXSJLWNO-UHFFFAOYSA-N 4-(1-cyclopropylethoxy)-3-hydroxy-2h-furan-5-one Chemical compound C1CC1C(C)OC1=C(O)COC1=O GIYARLYXSJLWNO-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- RQYXUYMTXLCIRB-UHFFFAOYSA-N 4-chloro-1,1,1-trifluoro-3-methylbutane Chemical compound CC(CCl)CC(F)(F)F RQYXUYMTXLCIRB-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- JLBBYMYIYLJFFN-UHFFFAOYSA-N 4-fluorobutan-2-one Chemical compound CC(=O)CCF JLBBYMYIYLJFFN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- YBDRFJXGJQULGH-UHFFFAOYSA-N 4-methyl-1h-pyridin-2-one Chemical compound CC1=CC=NC(O)=C1 YBDRFJXGJQULGH-UHFFFAOYSA-N 0.000 description 1
- GRDPSSWVXSPXHK-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfanylphenyl)furan-2-one Chemical compound C1=CC(SC)=CC=C1C1=CC(=O)OC1(C)C GRDPSSWVXSPXHK-UHFFFAOYSA-N 0.000 description 1
- HQPWJTVGSDAYAA-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-(piperidine-1-carbonyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1C(=O)N1CCCCC1 HQPWJTVGSDAYAA-UHFFFAOYSA-N 0.000 description 1
- HEUMSYRGLQWJQL-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-quinazolin-4-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC=2C3=CC=CC=C3N=CN=2)=C1C1=CC=C(S(C)(=O)=O)C=C1 HEUMSYRGLQWJQL-UHFFFAOYSA-N 0.000 description 1
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
- GFJMOZYIDADKLJ-UHFFFAOYSA-N 5-bromo-2-chloro-3-methoxypyridine Chemical compound COC1=CC(Br)=CN=C1Cl GFJMOZYIDADKLJ-UHFFFAOYSA-N 0.000 description 1
- SZFUWUOHDRMCKD-UHFFFAOYSA-N 5-chloro-1h-pyridin-2-one Chemical compound OC1=CC=C(Cl)C=N1 SZFUWUOHDRMCKD-UHFFFAOYSA-N 0.000 description 1
- KLULSYPVWLJZAO-UHFFFAOYSA-N 5-fluoro-1h-pyridin-2-one Chemical compound OC1=CC=C(F)C=N1 KLULSYPVWLJZAO-UHFFFAOYSA-N 0.000 description 1
- ISKZAFHLGSFFDN-UHFFFAOYSA-N 5-methoxy-5-methyl-4-(4-methylsulfonylphenyl)-3-phenylsulfanylfuran-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(OC)(C)OC(=O)C=1SC1=CC=CC=C1 ISKZAFHLGSFFDN-UHFFFAOYSA-N 0.000 description 1
- PFYCGEZLYBVOOJ-UHFFFAOYSA-N 5-methyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxy-5-propylfuran-2-one Chemical compound CCCC1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 PFYCGEZLYBVOOJ-UHFFFAOYSA-N 0.000 description 1
- CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- GHSRMSJVYMITDX-UHFFFAOYSA-N 6-chloro-2-methyl-3-nitropyridine Chemical compound CC1=NC(Cl)=CC=C1[N+]([O-])=O GHSRMSJVYMITDX-UHFFFAOYSA-N 0.000 description 1
- LKBKDKVMHWPZDB-UHFFFAOYSA-N 6-methoxypyridin-3-ol Chemical compound COC1=CC=C(O)C=N1 LKBKDKVMHWPZDB-UHFFFAOYSA-N 0.000 description 1
- DHLUJPLHLZJUBW-UHFFFAOYSA-N 6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C=N1 DHLUJPLHLZJUBW-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DSAWRSMCZDXMID-UHFFFAOYSA-N BrC1=CC=C(C=C1)SC.CC(C(O)C1=CC=C(C=C1)S(=O)(=O)C)=C Chemical compound BrC1=CC=C(C=C1)SC.CC(C(O)C1=CC=C(C=C1)S(=O)(=O)C)=C DSAWRSMCZDXMID-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- NNFJIUVBNVTTIU-UHFFFAOYSA-N CC1(CC(CC1)O)C.IC1CC(CC1)(C)C Chemical compound CC1(CC(CC1)O)C.IC1CC(CC1)(C)C NNFJIUVBNVTTIU-UHFFFAOYSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000238558 Eucarida Species 0.000 description 1
- NYOPBOBUQHXABP-UHFFFAOYSA-N FC=1C=C(OCC(=O)O)C=CC1F.C(=C)C(=O)COC1=CC(=C(C=C1)F)F Chemical compound FC=1C=C(OCC(=O)O)C=CC1F.C(=C)C(=O)COC1=CC(=C(C=C1)F)F NYOPBOBUQHXABP-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- AAUCSFGSACZRQQ-UHFFFAOYSA-K P(=O)([O-])([O-])[O-].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+] Chemical compound P(=O)([O-])([O-])[O-].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+].C(CCCCCCCCCCCCCCCCC)[Mg+] AAUCSFGSACZRQQ-UHFFFAOYSA-K 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 238000006202 Sharpless epoxidation reaction Methods 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- OZNQAUJKKFYVHT-UHFFFAOYSA-N [2-methyl-1-(4-methylsulfonylphenyl)-1-oxopropan-2-yl] 2-(2,4-difluorophenoxy)acetate Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(=O)C(C)(C)OC(=O)COC1=CC=C(F)C=C1F OZNQAUJKKFYVHT-UHFFFAOYSA-N 0.000 description 1
- NDFOSUWVHROLRH-UHFFFAOYSA-N [2-methyl-1-(4-methylsulfonylphenyl)-1-oxopropan-2-yl] 2-(diethylamino)acetate Chemical compound CCN(CC)CC(=O)OC(C)(C)C(=O)C1=CC=C(S(C)(=O)=O)C=C1 NDFOSUWVHROLRH-UHFFFAOYSA-N 0.000 description 1
- ASSNHLBDUBAWHK-UHFFFAOYSA-K [Al](Cl)(Cl)Cl.CC(C(=O)C1=CC=C(C=C1)SC)C Chemical compound [Al](Cl)(Cl)Cl.CC(C(=O)C1=CC=C(C=C1)SC)C ASSNHLBDUBAWHK-UHFFFAOYSA-K 0.000 description 1
- FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical compound [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 1
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CUZRHAZHEIPAQG-UHFFFAOYSA-N cyclopentyl-(4-methylsulfanylphenyl)methanone Chemical compound C1=CC(SC)=CC=C1C(=O)C1CCCC1 CUZRHAZHEIPAQG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- NUFBGJAEANEZKW-UHFFFAOYSA-N cyclopropyloxycyclopropane Chemical compound C1CC1OC1CC1 NUFBGJAEANEZKW-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- CAEMOCUMMOVWCN-UHFFFAOYSA-N diphosphono hydrogen phosphate phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O CAEMOCUMMOVWCN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003559 enprostil Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LCFLJHXAQJKTIM-UHFFFAOYSA-N ethyl 2-(3-chloro-4-hydroxyphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(O)C(Cl)=C1 LCFLJHXAQJKTIM-UHFFFAOYSA-N 0.000 description 1
- XNRZTVSPTISLTR-UHFFFAOYSA-N ethyl 5,5-dimethyl-4-(4-methylsulfonylphenyl)-2-oxofuran-3-carboxylate Chemical compound CC1(C)OC(=O)C(C(=O)OCC)=C1C1=CC=C(S(C)(=O)=O)C=C1 XNRZTVSPTISLTR-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 102000053332 human PTGS1 Human genes 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- CSNXUYRHPXGSJD-UHFFFAOYSA-N isoquinolin-5-ol Chemical compound N1=CC=C2C(O)=CC=CC2=C1 CSNXUYRHPXGSJD-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- PEQJBOMPGWYIRO-UHFFFAOYSA-N n-ethyl-3,4-dimethoxyaniline Chemical compound CCNC1=CC=C(OC)C(OC)=C1 PEQJBOMPGWYIRO-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- UQDVHJGNIFVBLG-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O UQDVHJGNIFVBLG-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical class C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HERCSPPGAAQXBN-UHFFFAOYSA-N propan-2-yl 2-fluoroacetate Chemical compound CC(C)OC(=O)CF HERCSPPGAAQXBN-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 201000007183 prothrombin deficiency Diseases 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- OVYWMEWYEJLIER-UHFFFAOYSA-N quinolin-6-ol Chemical compound N1=CC=CC2=CC(O)=CC=C21 OVYWMEWYEJLIER-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XKGLSKVNOSHTAD-UHFFFAOYSA-N valerophenone Chemical compound CCCCC(=O)C1=CC=CC=C1 XKGLSKVNOSHTAD-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式Iの化合物又はその薬物的に許容される塩。 [式中、 Xは、 (a)CH2、 (b)CHOH、 (c)CO、 (d)O、 (e)S、及び (f)N(R15) からなる群から選択され、但し、R3及びR4が (1)共に水素、 (2)共にC1-10アルキル又は (3)それらが結合している炭素と一緒に結合して、3、4、5、6又は 7個の原子の飽和単環式炭素環を形成する以外であるとき、XはCO、O、S又 はN(R15)から選択される、 Yは、 (a)C(R11)(R12)、 (b)CO、 (c)O、及び (d)S からなる群から選択され、 R1は、 (a)SO2CH3、 (b)SO2NR16R17、 (c)SO2NHC(O)CF3、 (d)S(O)(NH)NH2、 (e)S(O)(NH)NHC(O)CF3、 (f)P(O)(CH3)NH2、及び (g)P(O)(CH3)2 からなる群から選択され、 R2は、 (a)C1-10アルキル、 (b)モノ−、ジ−又はトリ−置換フェニル又はナフチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルコキシ、 (4)C1-10アルキルチオ、 (5)CN、 (6)C1-6フルオロアルキル、 (7)C1-10アルキル、 (8)N3、 (9)−CO2H、 (10)−CO2−C1-10アルキル、 (11)−C(R5)(R6)−OH、 (12)−C(R5)(R6)−O−C1-4アルキル、 (13)−C1-6アルキル−CO2−R5、 (14)ベンジルオキシ、 (15)−O−(C1-6アルキル)−CO2R5、及び (16)−O−(C1-6アルキル)−NR5R6 からなる群から選択される)、 (c)モノ−、ジ−又はトリ−置換ヘテロアリール(但し、ヘテロアリール は、5個の原子の単環式芳香族環であり、該環は、S、O若しくはNである1個 のヘテロ原子及び任意に1、2若しくは3個の追加のN原子を有するか又はヘテ ロアリールは、6個の原子の単環式環であり、該環は、Nである1個のヘテロ原 子及び任意に1、2若しくは3個の追加のN原子を有し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-10アルキル、 及び (11)C1-6フルオロアルキル からなる群から選択される)、 (d)モノ−又はジ−置換ベンゾ複素環(但し、複素環は、O、S又はNから 独立に選択された1個又は2個のヘテロ原子を含有してよい5、6又は7損環で あり、これにはカルボニル基又はスルホニル基が含有されてよく、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-10アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、 (e)O、S又はNから選択された1個又は2個のヘテロ原子を含有し、そし て任意にカルボニル基又はスルホニル基を含有する、5、6又は7員のヘテロシ クロアルキル基、 (f)モノ−又はジ−置換ベンゾ炭素環(但し、炭素環は、任意にカルボニル 基を含有する5、6又は7員環であり、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-10アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、 (g)O、S又はNから独立に選択される2〜5個のヘテロ原子を含有する、 8、9又は10員のモノ−又はジ−置換二環式ヘテロアリール(但し、各環は少 なくとも1個のヘテロ原子を含有し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-10アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、 からなる群から選択され、 R3は、水素、C1-10アルキル、CH2OR7、CN、CH2CN、C1-6フルオロ アルキル、F、CON(R7)2、モノ−若しくはジ−置換フェニル、モノ−若し くはジ−置換ベンジル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若し くはジ−置換ヘテロアリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-4アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)であり、 R4は、 (a)水素、 (b)C1-10アルキル、 (c)C1-10アルコキシ、 (d)C1-10アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SH、 (h)−SCOR7、 (i)−OCO2R8、 (j)−SCO2R8、 (k)OCON(R7)2、 (l)SCON(R7)2、及び (m)C1-6フルオロアルキル であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形成し、 R5及びR6は、それぞれ独立に、 (a)水素、及び (b)C1-10アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7は独立に、 (a)水素、 (b)C1-6アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、CN又はCF3であってよい) からなる群から選択されるか又は2個のR7基は、それらが結合している窒素と 一緒に、任意に追加のO、S若しくはNR5を含有する、5、6若しくは7個の 原子の飽和単環式環を形成し、 各R8は独立に、 (a)C1-6アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハ ロ、C1-6アルキル、C1-6アルコキシ、C1-6アルキルチオ、CN又はCF3であ ってよい)、及び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 R9及びR10は、独立に、 (a)水素、及び (b)C1-7アルキル からなる群から選択されるか又はR9とR10とは、それらが結合している炭素原 子と一緒に、カルボニル又はチオカルボニル基を形成し、 R11及びR12は、独立に、 (a)水素、 (b)モノ−若しくはジ−置換フェニル、モノ−若しくはジ−置換ベンジル、 モノ−若しくはジ−置換ヘテロアリール又はモノ−若しくはジ−置換ヘテロアリ ールメチル(但し、置換基は、 (1)水素、 (2)フルオロ、クロロ、ブロモ及びヨード、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R13)(R14)−OH、 (10)−C(R13)(R14)−O−C1-4アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、又は (c)C1-7アルキル、CH2OR7、CN、CH2CN、C1-6フルオロアルキ ル、CON(R7)2、F若しくはOR7であるか又はR11とR12とは、それらが 結合している炭素と一緒に、3、4、5、6若しくは7個の原子の飽和単環式炭 素環を形成し、 R13及びR14は、独立に、 (a)水素、及び (b)C1-7アルキル からなる群から選択されるか又はR13とR14とは、それらが結合している炭素と 一緒に、カルボニル、−C(=S)−又は3、4、5、6若しくは7個の原子の 飽和単環式炭素環を形成し、 R15は、 (a)水素、 (b)C1-10アルキル、 (c)モノ−、ジ−又はトリ−置換フェニル又はナフチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルコキシ、 (4)C1-10アルキルチオ、 (5)CN、 (6)C1-6フルオロアルキル、 (7)C1-10アルキル、 (8)N3、 (9)−CO2H、 (10)−CO2−C1-10アルキル、 (11)−C(R5)(R6)−OH、 (12)−C(R5)(R6)−O−C1-4アルキル、 (13)−C1-6アルキル−CO2−R5、 (14)ベンジルオキシ、 (15)−O−(C1-6アルキル)−CO2R5、及び (16)−O−(C1-6アルキル)−NR5R6 からなる群から選択される)、 (d)モノ−、ジ−又はトリ−置換ヘテロアリール(但し、ヘテロアリール は、5個の原子の単環式芳香族環であり、該環は、S、O若しくはNである1個 のヘテロ原子及び任意に1、2若しくは3個の追加のN原子を有するか又はヘテ ロアリールは、6個の原子の単環式環であり、該環は、Nである1個のヘテロ原 子及び任意に1、2若しくは3個の追加のN原子を有し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-10アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、 (e)モノ−又はジ−置換ベンゾ複素環(但し、複素環は、O、S又はNから 独立に選択された1個又は2個のヘテロ原子を含有してよい5、6又は7員環で あり、これにはカルボニル基又はスルホニル基が含有されてよく、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-10アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、 (f)O、S又はNから選択された1個又は2個のヘテロ原子を含有し、そし て任意にカルボニル基又はスルホニル基を含有する、5、6又は7員のヘテロシ クロアルキル基、 (g)モノ−又はジ−置換ベンゾ炭素環(但し、炭素環は、任意にカルボニル 基を含有する5、6又は7員環であり、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)N3、 (9)−C(R5)(R6)−OH、 (10)−C(R5)(R6)−O−C1-4アルキル、及び (11)C1-6フルオロアルキル からなる群から選択される)、 からなる群から選択され、 R16及びR17は、独立に、 (a)水素、 (b)C1-10アルキル、 (c)C1-10アルカン酸、 (d)C1-10アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-10アルキ ル、C1-10アルコキシ、C1-10アルキルチオ、C1-10アルカン酸、C1-10アルキ ルアミン、CN、CO2H又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-10アルキ ル、C1-10アルコキシ、C1-10アルキ ルチオ、C1-10アルカン酸、C1-10アルキルアミン、CN、CO2H又はCF3で ある) からなる群から選択されるか又はR16及びR17は、それらが結合している窒素と 一緒に、任意に追加のO、S若しくはNR5を含有する、5、6若しくは7個の 原子の飽和単環式環を形成する。] 2.R9及びR10が、それらが結合している炭素原子と一緒に、カルボニルを形 成する請求の範囲第1項記載の化合物。 3.Xが、 (a)CH2、及び (b)O からなる群から選択され、 Yが、 (a)CH2、及び (b)O からなる群から選択され、 R1が、 (a)SO2CH3、 (b)SO2NR16R17、及び (c)S(O)(NH)NH2 からなる群から選択され、 R2が、 (a)C1-6アルキル、 (b)モノ−、ジ−又はトリ−置換フェニル又はナフチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルコキシ、 (4)C1-6アルキルチオ、 (5)CN、 (6)C1-4フルオロアルキル、 (7)C1-6アルキル、 (8)−CO2H、 (9)−CO2−C1-10アルキル、 (10)−C(R5)(R6)−OH、 (11)−C(R5)(R6)−O−C1-4アルキル、 (12)−C1-6アルキル−CO2−R5、及び (13)−O−(C1-6アルキル)−CO2R5、 からなる群から選択される)、及び (c)モノ−、ジ−又はトリ−置換ヘテロアリール(但し、ヘテロアリール は、5個の原子の単環式芳香族環であり、該環は、S、O若しくはNである1個 のヘテロ原子及び任意に1、2若しくは3個の追加のN原子を有するか又はヘテ ロアリールは、6個の原子の単環式環であり、該環は、Nである1個のヘテロ原 子及び任意に1、2若しくは3個の追加のN原子を有し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)、及び (d)モノ−又はジ−置換ベンゾ複素環(但し、複素環は、O、S又はNから 独立に選択された1個又は2個のヘテロ原子 を含有してよい5、6又は7員環であり、これにはカルボニル基又はスルホニル 基が含有されてよく、置換基は、 (1)水素、 (2)ハロ、 (3)C1-10アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)、及び (e)O、S又はNから選択された1個又は2個のヘテロ原子を含有し、そし て任意にカルボニル基又はスルホニル基を含有する、5、6又は7員のヘテロシ クロアルキル基、 (f)モノ−又はジ−置換ベンゾ炭素環(但し、炭素環は、任意にカルボニル 基を含有する5、6又は7員環であり、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、 (8)−C(R5)(R6)−OH、 からなる群から選択される)、及び (g)O、S又はNから独立に選択される2〜5個のヘテロ原子を含有する、 8、9又は10員のモノ−又はジ−置換二環式ヘテロアリール(但し、各環は少 なくとも1個のヘテロ原子を含有し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-10アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)、 からなる群から選択され、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、CON(R7)2、モノ−若しくはジ−置換フェニル、モノ−若しく はジ−置換ベンジル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しく はジ−置換ヘテロアリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)であり、そして R4が、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルコキシ、 (d)C1-6アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SCOR7、 (h)−OCO2R8、及び (j)−SCO2R8、 であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形成し、 R5及びR6が、それぞれ独立に、 (a)水素、及び (b)C1-6アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7が独立に、 (a)水素、 (b)C1-4アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 各R8が独立に、 (a)C1-4アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCFであってよい) からなる群から選択され、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成し、 R16及びR17が、独立に、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルカン酸、 (d)C1-6アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、CO2H又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、CO2H又はCF3である) からなる群から選択される、 請求の範囲第2項記載の化合物。 4.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、 (b)S(O)2NR16R17、及び (c)S(O)(NH)NH2 からなる群から選択され、 R2が、 モノ−、ジ−又はトリ−置換フェニル又はナフチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルコキシ、 (4)C1-4アルキルチオ、 (5)CN、 (6)C1-3フルオロアルキル、 (7)C1-4アルキル、 (8)−CO2H、 (9)−CO2−C1-10アルキル、及び (10)−C(R5)(R6)−OH からなる群から選択される) からなる群から選択され、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、CON(R7)2、モノ−若し くはジ−置換フェニル、モノ−若しくはジ−置換ベンジル、モノ−若しくはジ− 置換ヘテロアリール又はモノ−若しくはジ−置換ヘテロアリールメチル(但し、 置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)であり、そして R4が、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルコキシ、 (d)C1-6アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SCOR7、 (h)−OCO2R8、及び (j)−SCO2R8、 であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形成し、 R5及びR6は、それぞれ独立に、 (a)水素、及び (b)C1-6アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7が独立に、 (a)水素、 (b)C1-4アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハ ロ、C1-4アルキル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であ ってよい) からなる群から選択され、 各R8が独立に、 (a)C1-4アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成し、 R16及びR17が、独立に、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルカン酸、 (d)C1-6アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、COOH又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、COOH又はCF3である) からなる群から選択される、 請求の範囲第3項記載の化合物。 5.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、 モノ−又はジ−置換フェニル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルコキシ、 (4)C1-4アルキルチオ、 (5)CN、 (6)C1-3フルオロアルキル、 (7)C1-4アルキル、 (8)−CO2H、 (9)−CO2−C1-10アルキル、 からなる群から選択される) からなる群から選択され、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、モノ−若しくはジ−置換フェニル、モノ−若しくはジ−置換ベンジ ル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しくはジ−置換ヘテロ アリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-3アルキル、 (4)C1-3アルコキシ、 (5)C1-3アルキルチオ、 (6)CN、及び (7)CF3、 からなる群から選択される)であり、そして R4が、 (a)水素、 (b)C1-3アルキル、 (c)C1-3アルコキシ、 (d)C1-3アルキルチオ、及び (e)−OH、 であり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第4項記載の化合物。 6.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、 モノ−又はジ−置換フェニル又はナフチル(但し、置換基は、 (1)水素、 (2)ハロ、 (5)CN、 (6)CF3、及び (7)C1-4アルキル からなる群から選択される) からなる群から選択され、 R3が、水素又はC1-3アルキルであり、 R4が、水素又はC1-3アルキルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第5項記載の化合物。 7.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、 モノ−又はジ−置換フェニル又はナフチル(但し、置換基は、 (1)水素、 (2)ハロ、 (5)CN、 (6)CF3、及び (7)C1-4アルキル からなる群から選択される) からなる群から選択され、 R3が、メチル又はエチルであり、 R4が、メチル又はエチルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第6項記載の化合物。 8.Xが、 (a)CH2、及び (b)O からなる群から選択され、 Yが、 (a)CH2、及び (b)O からなる群から選択され、 R1が、 (a)SO2CH3、 (b)SO2NR16R17、及び (c)S(O)(NH)NH2 からなる群から選択され、 R2が、 (a)モノ−、ジ−又はトリ−置換ヘテロアリール(但し、ヘテロアリール は、5個の原子の単環式芳香族環であり、該環は、S、O若しくはNである1個 のヘテロ原子及び任意に1、2若しくは3個の追加のN原子を有するか又はヘテ ロアリールは、6個の原子の単環式環であり、該環は、Nである1個のヘテロ原 子及び任意に1、2若しくは3個の追加のN原子を有し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH からなる群から選択される)、 (b)モノ−又はジ−置換ベンゾ複素環(但し、複素環は、O、S又はNから 独立に選択された1個又は2個のヘテロ原子を含有してよい5、6又は7員環で あり、これにはカルボニル基又はスルホニル基が含有されてよく、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-10アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)、 (c)O、S又はNから選択された1個又は2個のヘテロ原子を含有し、そし て任意にカルボニル基又はスルホニル基を含有する、5、6又は7員のヘテロシ クロアルキル基、 (d)モノ−又はジ−置換ベンゾ炭素環(但し、炭素環は、任意にカルボニル 基を含有する5、6又は7員環であり、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)、及び (e)O、S又はNから独立に選択される2、3、4又は5個のヘテロ原子を 含有する、8、9又は10員のモノ−又はジ −置換二環式ヘテロアリール(但し、各環は少なくとも1個のヘテロ原子を含有 し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)、 からなる群から選択され、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-3フルオロア ルキル、F、CON(R7)2、モノ−若しくはジ−置換フェニル、モノ−若しく はジ−置換ベンジル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しく はジ−置換ヘテロアリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)であり、 R4が、 (a)水素、 (b)C1-4アルキル、 (c)C1-4アルコキシ、 (d)C1-4アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SCOR7、 (h)−OCO2R8、及び (i)−SCO2R8、 であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形 成し、 R5及びR6が、それぞれ独立に、 (a)水素、及び (b)C1-4アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7が独立に、 (a)水素、 (b)C1-4アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 各R8が独立に、 (a)C1-4アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 R9及びR10が、それらが結合している炭素原子と一緒に、カルボニルを形成し 、 R16及びR17が、独立に、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルカン酸、 (d)C1-6アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、CO2H又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハ ロ、C1-6アルキル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、 C1-6アルキルアミン、CN、CO2H又はCF3である) からなる群から選択される、 請求の範囲第3項記載の化合物。 9.Xが、 (a)CH2、及び (b)O からなる群から選択され、 Yが、 (a)CH2、及び (b)O からなる群から選択され、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、 モノ−、ジ−又はトリ−置換ヘテロアリール(但し、ヘ テロアリールは、5個の原子の単環式芳香族環であり、該環は、S、O若しくは Nである1個のヘテロ原子及び任意に1、2若しくは3個の追加のN原子を有す るか又はヘテロアリールは、6個の原子の単環式環であり、該環は、Nである1 個のヘテロ原子及び任意に1、2若しくは3個の追加のN原子を有し、置換基は 、 (1)水素、 (2)ハロ、 (3)C1-6アルキル、 (4)C1-6アルコキシ、 (5)C1-6アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH からなる群から選択される)、 からなる群から選択され、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-3フルオロア ルキル、F、CON(R7)2、モノ−若しくはジ−置換フェニル、モノ−若しく はジ−置換ベンジル、モ ノ−若しくはジ−置換ヘテロアリール又はモノ−若しくはジ−置換ヘテロアリー ルメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)であり、 R4が、 (a)水素、 (b)C1-4アルキル、 (c)C1-4アルコキシ、 (d)C1-4アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SCOR7、 (h)−OCO2R8、及び (i)−SCO2R8、 であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形成し、 R5及びR6が、それぞれ独立に、 (a)水素、及び (b)C1-4アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7が独立に、 (a)水素、 (b)C1-4アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチ オ、CN又はCF3であってよい) からなる群から選択され、 各R8が独立に、 (a)C1-4アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成し、 R16及びR17が、独立に、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルカン酸、 (d)C1-6アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハ ロ、C1-6アルキル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、 C1-6アルキルアミン、CN、CO2H又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、CO2H又はCF3である) からなる群から選択される、 請求の範囲第8項記載の化合物。 10.R2が、モノ−又はジ−置換ヘテロアリール(但し、ヘテロアリールは、 (1)フラニル、 (2)ジアジニル、 (3)イミダゾリル、 (4)イソオキサゾリル、 (5)イソチアゾリル、 (6)オキサジアゾリル、 (7)オキサゾリル、 (8)ピラゾリル、 (9)ピリジル、 (10)ピロリル、 (11)テトラジニル、 (12)テトラゾリル、 (13)チアジアゾリル、 (14)チアゾリル、 (15)チエニル、 (16)トリアジニル、又は (17)トリアゾリル からなる群から選択され、置換基は (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、及び (7)CF3 からなる群から選択される) である、請求の範囲第9項記載の化合物。 11.R2が、モノ−又はジ−置換ヘテロアリール(但し、ヘテロアリールは、 (1)フラニル、 (2)ジアジニル、 (3)イミダゾリル、 (4)イソオキサゾリル、 (5)イソチアゾリル、 (6)オキサジアゾリル、 (7)オキサゾリル、 (8)ピラゾリル、 (9)ピリジル、 (10)ピロリル、 (11)チアゾリル、及び (12)チエニル、 からなる群から選択され、置換基は (1)水素、 (2)ハロ、 (3)C1-3アルキル、 (4)C1-3アルコキシ、及び (7)CF3 からなる群から選択される) である、請求の範囲第10項記載の化合物。 12.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NH2 からなる群から選択され、 R2が、モノ−又はジ−置換ヘテロアリール(但し、ヘテロアリールは、 (1)フラニル、 (2)ジアジニル、 (3)イミダゾリル、 (4)オキサジアゾリル、 (5)ピラゾリル、 (6)ピリジル、 (7)ピロリル、 (8)チアゾリル、及び (9)チエニル、 からなる群から選択され、置換基は (1)水素、 (2)ハロ、 (3)メチル、 (4)メトキシ、及び (5)CF3 からなる群から選択される) であり、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、モノ−若しくはジ−置換フェニル、モノ−若しくはジ−置換ベンジ ル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しくはジ−置換ヘテロ アリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-3アルキル、 (4)C1-3アルコキシ、 (5)C1-3アルキルチオ、 (6)CN、及び (7)CF3、 からなる群から選択される)であり、 R4が、 (a)水素、 (b)C1-3アルキル、 (c)C1-3アルコキシ、 (d)C1-3アルキルチオ、及び (e)−OH、 であり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第11項記載の化合物。 13.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NH2 からなる群から選択され、 R2が、モノ−又はジ−置換ヘテロアリール(但し、ヘテロアリールは、 (1)フラニル、 (2)ジアジニル、 (3)イミダゾリル、 (4)オキサジアゾリル、 (5)ピラゾリル、 (6)ピリジル、 (7)チアゾリル、 (8)チエニル、 からなる群から選択され、置換基は (1)水素、 (2)Br、Cl又はF、 (3)メチル、 (4)メトキシ、及び (5)CF3 からなる群から選択される) であり、 R3が、水素又はC1-3アルキルであり、 R4が、水素又はC1-3アルキルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第12項記載の化合物。 14.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NH2 からなる群から選択され、 R2が、モノ−又はジ−置換ピリジル(但し、置換基は (1)水素、 (2)Br、Cl又はF、 (3)メチル、 (4)メトキシ、及び (5)CF3 からなる群から選択される) であり、 R3が、水素又はC1-3アルキルであり、 R4が、水素又はC1-3アルキルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第13項記載の化合物。 15.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NH2 からなる群から選択され、 R3が、メチル又はエチルであり、 R4が、メチル又はエチルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第14項記載の化合物。 16.(1)3−(3,4−ジフルオロフェノキシ)−5,5−ジメチル−4− (4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (2)3−(3−フルオロフェノキシ)−5,5−ジメチル− 4−(4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (3)3−(3,5−ジフルオロフェノキシ)−5,5−ジメチル−4−(メチ ルスルホニル)フェニル)−5H−フラン−2−オン、 (4)3−フェノキシ−5,5−ジメチル−4−(4−(メチルスルホニル)フ ェニル)−5H−フラン−2−オン、 (5)3−(2,4−ジフルオロフェノキシ)−5,5−ジメチル−4−(4− (メチルスルホニル)フェニル)−5H−フラン−2−オン、 (6)3−(4−クロロフェノキシ)−5,5−ジメチル−4−(4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (7)3−(3,4−ジクロロフェノキシ)−5,5−ジメチル−4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (8)3−(4−フルオロフェノキシ)−5,5−ジメチル−4−(4−(メチ ルスルホニル)フェニル)−5H−フラン−2−オン、 (9)3−(4−フルオロフェニルチオ)−5,5−ジメチル−4−(4−(メ チルスルホニル)フェニル)−5H−フラン−2−オン、 (10)3−(3,5−ジフルオロフェニルチオ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (11)3−フェニルチオ−5,5−ジメチル−4−(4−(メチルスルホニル )フェニル)−5H−フラン−2−オン、 (12)3−(N−フェニルアミノ)−5,5−ジメチル−4−(4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (13)3−(N−メチル−N−フェニルアミノ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (14)3−シクロヘキシルオキシ−5,5−ジメチル−4−(4−(メチルス ルホニル)フェニル)−5H−フラン−2−オン、 (15)3−フェニルチオ−4−(4−(メチルスルホニル)フェニル)−5H −フラン−2−オン、 (16)3−ベンジル−5,5−ジメチル−4−(4−(メチルスルホニル)フ ェニル)−5H−フラン−2−オン、 (17)3−(3,4−ジフルオロフェニルヒドロキシメチル)−5,5−ジメ チル−4−(4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (18)3−(3,4−ジフルオロベンゾイル)−5,5−ジメチル−4−(4 −(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (19)3−ベンゾイル−5,5−ジメチル−4−(4−(メチルスルホニル) フェニル)−5H−フラン−2−オン、 (20)4−(4−(メチルスルホニル)フェニル)−3−フェノキシ−1−オ キサスピロ[4.4]ノン−3−エン−2−オン、 (21)4−(4−(メチルスルホニル)フェニル)−3−フェニルチオ−1− オキサスピロ[4.4]ノン−3−エン−2−オン、 (22)4−(2−オキソ−3−フェニルチオ−1−オキサ−スピロ[4.4] ノン−3−エン−4−イル)ベンゼンスルホンアミド、 (23)3−(4−フルオロベンジル)−5,5−ジメチル−4−(4−(メチ ルスルホニル)フェニル)−5H−フラン−2−オン、 (24)3−(3,4−ジフルオロフェノキシ)−5−メトキシ−5−メチル− 4−(4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (25)3−(5−クロロ−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (26)3−(2−ピリジルオキシ)−5,5−ジメチル−4−(4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (27)3−(6−メチル−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (28)3−(3−イソキノリンオキシ)−5,5−ジメチル−4−(4−(メ チルスルホニル)フェニル)−5H−フラン−2−オン、 (29)3−(4−(メチルスルホニル)フェニル)−2−フ ェノキシシクロペント−2−エノン、及び (30)3−(4−(メチルスルホニル)フェニル)−2−(3,4−ジフルオ ロフェノキ)シクロペント−2−エノン からなる群から選択される、請求の範囲第1項記載の化合物。 17.非毒性で治療的に有効量の、請求の範囲第1、2、3、4、5、6、7、 8、9、10、11、12、13、14、15又は16項記載の、式(I)の化 合物又はその薬物的に許容される塩及び薬物的に許容される坦体からなる、非ス テロイド性抗炎症薬での治療を受けやすい炎症性疾患を治療するための薬物組成 物。 18.非毒性で治療的に有効量の、請求の範囲第1、2、3、4、5、6、7、 8、9、10、11、12、13、14、15又は16項記載の、式(I)の化 合物又はその薬物的に許容される塩及び薬物的に許容される坦体からなる、CO X−1よりはむしろCOX−2を選択的に阻害する活性薬剤によって有利に治療 されるシクロオキシゲナーゼ仲介疾患を治療するための薬物組成物。 19.非ステロイド性抗炎症薬での治療を受けやすい炎症性疾患の治療方法であ って、このような治療が必要である患者に、 非毒性で治療的に有効量の請求の範囲第1項記載の化合物及び薬物的に許容され る坦体を投薬することからなる方法。 20.COX−1よりはむしろCOX−2を選択的に阻害する活性薬剤によって 有利に治療されるシクロオキシゲナーゼ仲介疾患の治療方法であって、このよう な治療が必要である患者に、非毒性で治療的に有効量の請求の範囲第1項記載の 化合物を投薬することからなる方法。 21.Xが、 (a)CH2、及び (b)O からなる群から選択され、 Yが、 (a)CH2、及び (b)O からなる群から選択され、 R1が、 (a)SO2CH3、 (b)SO2NR16R17、及び (c)S(O)(NH)NH2 からなる群から選択され、 R2が、C1-6アルキルであり、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、CON(R7)2、モノ−若しくはジ−置換フェニル、モノ−若しく はジ−置換ベンジル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しく はジ−置換ヘテロアリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)であり、 R4が、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルコキシ、 (d)C1-6アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SCOR7、 (h)−OCO2R8、及び (i)−SCO2R8、 であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形成し、 R5及びR6が、それぞれ独立に、 (a)水素、及び (b)C1-6アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7が独立に、 (a)水素、 (b)C1-4アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 各R8が独立に、 (a)C1-4アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成し、 R16及びR17が、独立に、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルカン酸、 (d)C1-6アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、CO2H又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、CO2H又はCF3である) からなる群から選択される、 請求の範囲第3項記載の化合物。 22.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、 (b)S(O)2NR16R17、及び (c)S(O)(NH)NH2 からなる群から選択され、 R2が、C1-4アルキルであり、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、CON(R7)2、モノ−若しくはジ−置換フェニル、モノ−若しく はジ−置換ベンジル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しく はジ−置換ヘテロアリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-4アルキル、 (4)C1-4アルコキシ、 (5)C1-4アルキルチオ、 (6)CN、 (7)CF3、及び (8)−C(R5)(R6)−OH、 からなる群から選択される)であり、 R4が、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルコキシ、 (d)C1-6アルキルチオ、 (e)−OH、 (f)−OCOR7、 (g)−SCOR7、 (h)−OCO2R8、及び (i)−SCO2R8、 であるか又はR3とR4とは、それらが結合している炭素と一緒に、3、4、5、 6又は7個の原子の飽和単環式炭素環を形成し、 R5及びR6が、それぞれ独立に、 (a)水素、及び (b)C1-6アルキル からなる群から選択されるか又はR5とR6とは、それらが結合している原子と一 緒に、3、4、5、6又は7個の原子の飽和単環式環を形成し、 各R7が独立に、 (a)水素、 (b)C1-4アルキル、 (c)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (d)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 各R8が独立に、 (a)C1-4アルキル、 (b)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい)、及 び (c)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-4アルキ ル、C1-4アルコキシ、C1-4アルキルチオ、CN又はCF3であってよい) からなる群から選択され、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成し、 R16及びR17が、独立に、 (a)水素、 (b)C1-6アルキル、 (c)C1-6アルカン酸、 (d)C1-6アルキルアミン、 (e)フェニル又はモノ置換フェニル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、COOH又はCF3である)、及び (f)ベンジル又はモノ置換ベンジル(但し、置換基は、ハロ、C1-6アルキ ル、C1-6アルコキシ、C1-6アルキルチオ、C1-6アルカン酸、C1-6アルキルア ミン、CN、COOH又はCF3である) からなる群から選択される、 請求の範囲第21項記載の化合物。 23.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、プロピル又はブチルであり、 R3が、水素、C1-6アルキル、CH2OR7、CN、CH2CN、C1-4フルオロア ルキル、F、モノ−若しくはジ−置換フェニル、モノ−若しくはジ−置換ベンジ ル、モノ−若しくはジ−置換ヘテロアリール又はモノ−若しくはジ−置換ヘテロ アリールメチル(但し、置換基は、 (1)水素、 (2)ハロ、 (3)C1-3アルキル、 (4)C1-3アルコキシ、 (5)C1-3アルキルチオ、 (6)CN、及び (7)CF3、 からなる群から選択される)であり、 R4が、 (a)水素、 (b)C1-3アルキル、 (c)C1-3アルコキシ、 (d)C1-3アルキルチオ、及び (e)−OH、 であり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第22項記載の化合物。 24.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、プロピル又はブチルであり、 R3が、水素又はC1-3アルキルであり、 R4が、水素又はC1-3アルキルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第23項記載の化合物。 25.XがOであり、 YがOであり、 R1が、 (a)SO2CH3、及び (b)SO2NR16R17 からなる群から選択され、 R2が、イソプロピルであり、 R3が、メチル又はエチルであり、 R4が、メチル又はエチルであり、 R9及びR10が、それらが結合している炭素と一緒に、カルボニルを形成する、 請求の範囲第24項記載の化合物。 26.R16及びR17がそれぞれ水素である、請求の範囲第25項記載の化合物。 27.R1がSO2CH3である、請求の範囲第26項記載の化合物。 28.(a)5,5−ジメチル−4−(4−メチルスルホニルフェニル)−3− (5−ブロモピリジン−2−イルオキシ)−5H−フラン−2−オン、及び (b)5,5−ジメチル−4−(4−メチルスルホニルフェニル)−3−(2− プロポキシ)−5H−フラン−2−オン、又は その薬物的に許容される塩 からなる群から選択された、請求の範囲第1項記載の化合物。 29.5,5−ジメチル−4−(4−メチルスルホニルフェニル)−3−(2− プロポキシ)−5H−フラン−2−オン又はその薬物的に許容される塩である、 請求の範囲第1項記載の化合物。 30.非毒性で治療的に有効量の、請求の範囲第29項記載の化合物及び薬物的 に許容される坦体からなる、非ステロイド性抗炎症薬での治療を受けやすい炎症 性疾患を治療するための薬物組成物。 31.非ステロイド性抗炎症薬での治療を受けやすい炎症性疾患の治療方法であ って、このような治療が必要である患者に、非毒性で治療的に有効量の請求の範 囲第29項記載の化合物及び薬物的に許容される坦体を投薬することからなる方 法。 32.(1)2−(3,4−ジフルオロフェノキシ)−3−(4−メチルスルホ ニルフェニル)−シクロペント−2−エノン、 (2)3−(5−ベンゾチオフェニルオキシ)−5,5−ジメチル−4−(4− (メチルスルホニル)フェニル)−5H−フラン−2−オン、 (3)5,5−ジメチル−4−(4−メチルスルホニル−フェニル)−3−(ピ リジル−4−オキシ)−5H−フラン−2−オン、 (4)5,5−ジメチル−4−(4−メチルスルホニル−フェニル)−3−(ピ リジル−3−オキシ)−5H−フラン−2−オン、 (5)3−(2−メチル−5−ピリジルオキシ)−5,5−ジメチル−4−(4 −(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (6)3−(2−フルオロ−4−トリフルオロメチル)フェノキシ−4−(4− メチルスルホニル)フェニル)−5,5−ジメチル−5H−フラン−2−オン、 (7)3−(5−クロロ−2−ピリジルチオ)−5,5−ジメチル−4−(4− メチルスルホニル)フェニル)−5H−フラン−2−オン、 (8)2−(3,5−ジフルオロフェノキシ)−3−(4−メ チルスルホニルフェニル)−シクロペント−2−エノン、 (9)3−(2−ピリミジンオキシ)−5,5−ジメチル−4−(4−メチルス ルホニル)フェニル−5H−フラン−2−オン、 (10)3−(3−メチル−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (11)3−(3−クロロ−5−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (12)3−(3−(1,2,5−チアジアゾリル)オキシ)−4−(4−(メ チルスルホニル)フェニル)−5,5−ジメチル−5H−フラン−2−オン、 (13)3−(5−イソキノリンオキシ)−5,5−ジメチル−4−(4−メチ ルスルホニル)フェニル−5H−フラン−2−オン、 (14)3−(6−アミノ−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (15)3−(3−クロロ−4−フルオロ)フェノキシ−4−(メチルスルホニ ル)フェニル)−5,5−ジメチル−5H−フラン−2−オン、 (16)3−(6−キノリンオキシ)−5,5−ジメチル−4−(4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (17)3−(5−ニトロ−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (18)3−(2−チアゾリルチオ)−5,5−ジメチル−4−(4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (19)3−(3−クロロ−5−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (20)5,5−ジメチル−4−(4−メチルスルホニルフェニル)−3−(2 −プロポキシ)−5H−フラン−2−オン、 (21)3−(3−トリフルオロメチル)フェノキシ−4−(4−メチルスルホ ニル)フェニル)−5,5−ジメチル−5H− フラン−2−オン、 (22)5,5−ジメチル−(4−(4−メチルスルホニル)フェニル)−3− (ピペリジン−1−カルボニル)−5H−フラン−2−オン、 (23)5,5−ジメチル−3−(2−ブトキシ)−4−(4−メチルスルホニ ルフェニル)−5H−フラン−2−オン、 (24)5,5−ジメチル−4−(4−メチルスルホニルフェニル)−3−(3 −ペントキシ)−5H−フラン−2−オン、 (25)2−(5−クロロ−2−ピリジルオキシ)−3−(4−メチルスルホニ ル)フェニルシクロペント−2−エノン、 (26)3−(4−メチル−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (27)(5R)−3−(3,4−ジフルオロフェノキシ)−5−エチル−5− メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (28)(5R)−3−(4−クロロフェノキシ)−5−エチル−5−メチル− 4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (29)3−(2−メチル−3−ピリジルオキシ)−5,5−ジメチル−4−( 4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (30)3−(4−メチル−5−ニトロ−2−ピリジルオキシ)−5,5−ジメ チル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (31)3−(5−クロロ−4−メチル−2−ピリジルオキシ)−5,5−ジメ チル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (32)3−(5−フルオロ−4−メチル−2−ピリジルオキシ)−5,5−ジ メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (33)3−(3−クロロ−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (34)3−(4−フルオロフェノキシ)−5−メチル−4−(4−メチルスル ホニル)フェニル−5−プロピル−5H−フラン−2−オン、 (35)3−(N,N−ジエチルアミノ)−5,5−ジメチル −4−(4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (36)5,5−ジメチル−4−(4−メチルスルホニル−フェニル)−3−( 3,5−ジクロロ−2−ピリジルオキシ)−5H−フラン−2−オン、 (37)(5R)−3−(4−ブロモフェノキシ)−5−エチル−5−メチル− 4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (38)(5R)−3−(4−メトキシフェノキシ)−5−エチル−5−メチル −4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (39)(5R)−3−(5−クロロ−2−ピリジルオキシ)−5−メチル−4 −(4−メチルスルホニル)フェニル−5−(2,2,2−トリフルオロエチル )−5H−フラン−2−オン、 (40)3−(5−クロロ−2−ピリジルオキシ)−5−メチル−4−(4−メ チルスルホニル)フェニル−5−プロピル−5H−フラン−2−オン、 (41)3−(1−シクロプロピル−エトキシ)−5,5−ジ メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (42)5−メチル−4−(4−(メチルスルホニル)フェニル)−3−(2− (プロポキシ)−5−(2−トリフルオロエチル)−5H−フラン−2−オン、 (43)5(R)−5−エチル−5−メチル−4−(4−(メチルスルホニル) フェニル)−3−(2−プロポキシ)−5H−フラン−2−オン、 (44)5,5−ジメチル−3−(2,2−ジメチルプロピルオキシ)−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (45)5(R)−3−(1−シクロプロピル−エトキシ)−5−エチル−5− メチル−4−(4−(メチルスルホニル)フェニル−5H−フラン−2−オン、 (46)5(S)−5−エチル−5−メチル−4−(4−(メチルスルホニル) フェニル−3−(2−プロポキシ)−5H−フラン−2−オン、 (47)3−(1−シクロプロピルエトキシ)−5,5−ジメチル−4−(4− (メチルスルホニル)フェニル)−5H−フ ラン−2−オン、 (48)3−(1−シクロプロピルエトキシ)−5,5−ジメチル−4−(4− (メチルスルホニル)フェニル)−5H−フラン−2−オン、 (49)3−(シクロプロピルメトキシ)−5,5−ジメチル−4−(4−(メ チルスルホニル)フェニル)−5H−フラン−2−オン、 (50)5,5−ジメチル−3−(イソブトキシ)−4−(4−(メチルスルホ ニル)フェニル)−5H−フラン−2−オン、 (51)3−(4−ブロモフェノキシ)−5,5−ジメチル−4−(4−(メチ ルスルホニル)フェニル)−5H−フラン−2−オン、 (52)3−(2−キノリンオキシ)−5,5−ジメチル−4−(4−(メチル スルホニル)フェニル)−5H−フラン−2−オン、 (53)3−(2−クロロ−5−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (54)3−(6−ベンゾチアゾリルオキシ)−5,5−ジメ チル−4−(4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (55)3−(6−クロロ−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、 (56)3−(4−キナゾリルオキシ)−5,5−ジメチル−4−(4−(メチ ルスルホニル)フェニル)−5H−フラン−2−オン、 (57)(5R)−3−(5−フルオロ−2−ピリジルオキシ)−5−エチル− 5−メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン 、 (58)(5R)−3−(4−フルオロフェノキシ)−5−エチル−5−メチル −4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (59)(5R)−3−(5−フルオロ−2−ピリジルオキシ)−5−メチル− 4−(4−メチルスルホニル)フェニル−5−(2,2,2−トリフルオロエチ ル)−5H−フラン−2−オン、 (60)3−(1−イソキノリニルオキシ)−5,5−ジメチ ル−4−(メチルスルホニル)フェニル−5H−フラン−2−オン、 (61)(5R)−3−(4−フルオロフェノキシ)−5−メチル−4−(4− メチルスルホニル)フェニル−5−(2,2,2−トリフルオロエチル)−5H −フラン−2−オン、 (62)3−(3−フルオロ−2−ピリジルオキシ)−5,5−ジメチル−4− (4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (63)(5R)−3−(3,4−ジフルオロフェノキシ)−5−メチル−4− (4−メチルスルホニル)フェニル−5−(2,2,2−トリフルオロエチル) −5H−フラン−2−オン、 (64)(5R)−3−(5−クロロ−2−ピリジルオキシ)−5−エチル−5 −メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (65)3−(3,4−ジフルオロフェノキシ)−5−メチル−5−トリフルオ ロメチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (66)3−(3,4−ジフルオロフェノキシ)−5−メチル−4−(4−(メ チルスルホニル)フェニル)−5−プロピル −5H−フラン−2−オン、 (67)3−シクロブチルオキシ−5,5−ジメチル−4−(4−メチルスルホ ニルフェニル−5H−フラン−2−オン、 (68)3−(1−インダニルオキシ)−5,5−ジメチル−4−(4−(メチ ルスルホニル)フェニル)−5H−フラン−2−オン、 (69)3−(2−インダニルオキシ)−5,5−ジメチル−4−(4−メチル スルホニル)フェニル)−5H−フラン−2−オン、 (70)3−シクロペンチルオキシ−5,5−ジメチル−4−(4−メチルスル ホニルフェニル)−5H−フラン−2−オン、 (71)3−(3,3−ジメチルシクロペンチルオキシ)−5,5−ジメチル− 4−(4−メチルスルホニルフェニル)−5H−フラン−2−オン、 (72)3−イソプロポキシ−5−メチル−4−(4−メチルスルホニルフェニ ル)−5−プロピル−5H−フラン−2−オン、 (73)3−(2−メトキシ−5−ピリジルオキシ)−5,5−ジメチル−4− (4−メチルスルホニル)フェニル−5H− フラン−2−オン、 (74)3−(5−メチル−2−ピリジルオキシ)−5,5−ジメチル−4−( 4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (75)(5RS)−3−(3,4−ジフルオロフェノキシ)−5−メチル−4 −(4−メチルスルホニル)フェニル−5−(2,2,2−トリフルオロエチル )−5H−フラン−2−オン、 (76)3−(3−クロロ−4−メトキシフェノキシ)−5,5−ジメチル−4 −(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (77)(5R)−3−(3−クロロ−4−メトキシフェノキシ)−5−エチル −5−メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オ ン、 (78)(5R)−3−(4−クロロフェノキシ)−5−トリフルオロエチル− 5−メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン 、 (79)(5R)−3−(4−ブロモフェノキシ)−5−トリフルオロエチル− 5−メチル−4−(4−メチルスルホニル) フェニル−5H−フラン−2−オン、 (80)5−シクロプロピルメチル−3−(3,4−ジフルオロフェノキシ)− 5−メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン 、 (81)(5R)−3−(3−フルオロフェノキシ)−5−エチル−5−メチル −4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (82)(5R)−3−(4−クロロ−3−フルオロフェノキシ)−5−エチル −5−メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オ ン、 (83)(5R)−3−フェノキシ−5−エチル−5−メチル−4−(4−メチ ルスルホニル)フェニル−5H−フラン−2−オン、 (84)(5R)−3−(4−クロロ−3−メチルフェノキシ)−5−エチル− 5−メチル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン 、 (85)3−(4−クロロ−3−メチルフェノキシ)−5,5−ジメチル−4− (4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (86)(5R)−3−(5−ブロモ−2−ピリジルオキシ)−4−(4−メチ ルスルホニルフェニル)−5−メチル−5−(2,2,2−トリフルオロエチル )−5H−フラン−2−オン、 (87)(5R)−3−(5−ブロモ−2−ピリジルオキシ)−4−(4−メチ ルスルホニルフェニル)−5−エチル−5−メチル−5H−フラン−2−オン、 (88)3−(5−クロロ−6−メチル−2−ピリジルオキシ)−5,5−ジメ チル−4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (89)3−(5−シクロプロピル−2−ピリジルオキシ)−5,5−ジメチル −4−(4−メチルスルホニル)フェニル−5H−フラン−2−オン、 (90)3−(1−シクロプロピルエトキシ)−4−(4−メチルスルホニル) フェニル−5H−フラン−2−オン、及び (91)3−(シクロプロピルメトキシ)−4−(4−メチルスルホニル)フェ ニル−5H−フラン−2−オン、 からなる群から選択された請求の範囲第1項記載の化合物。 33.R16及びR17が、それぞれ同時に水素である、請求の 範囲第1、5、6、7、21、23又は24項記載の化合物。 34.R1がSO2CH3である、請求の範囲第1、5、6、7、21、23又は 24項記載の化合物。 35.請求の範囲第1、2、3、4、5、6、7、8、9、10、11、12、 13、14、15、16、21、22、23、24、25、26、27、28、 29、32、22又は34項に定義される、式(I)の化合物の薬物的に許容さ れる塩。 36.炎症性疾患を治療する際に使用するための、請求の範囲第1、2、3、4 、5、6、7、8、9、10、11、12、13、14、15、16、21、2 2、23、24、25、26、27、28、29、32、22又は34項に定義 される、式(I)の化合物又はその薬物的に許容される塩。 37.シクロオキシゲナーゼ仲介疾患を治療する際に使用するための、請求の範 囲第1、2、3、4、5、6、7、8、9、10、11、12、13、14、1 5、16、21、22、23、24、25、26、27、28、29、32、2 2又は34項に定義される、式(I)の化合物又はその薬物的に許容される塩。 38.炎症性疾患を治療するための薬剤の製造に於ける、請求の範囲第1、2、 3、4、5、6、7、8、9、10、11、12、13、14、15、16、2 1、22、23、24、25、26、27、28、29、32、22又は34項 に定義される、式(I)の化合物又はその薬物的に許容される塩の使用。 39.薬物的に許容される坦体と一緒にして、許容される抗炎症性量の、請求の 範囲第1、2、3、4、5、6、7、8、9、10、11、12、13、14、 15、16、21、22、23、24、25、26、27、28、29、32、 22又は34項に定義される、式(I)の化合物からなる、抗炎症性薬物組成物 。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US537195P | 1995-10-13 | 1995-10-13 | |
GB9602939.2 | 1996-02-13 | ||
GBGB9602939.2A GB9602939D0 (en) | 1996-02-13 | 1996-02-13 | (Methylsulfony)phenyl-2-(5h)-furanones as cox-2 inhibitors |
US1163796P | 1996-02-14 | 1996-02-14 | |
GB60/011,637 | 1996-03-18 | ||
GBGB9605645.2A GB9605645D0 (en) | 1996-03-18 | 1996-03-18 | (Methylsulfonyl)phenyl-2-(5H)- furanones as cox-2 inhibitors |
GB9605645.2 | 1996-03-18 | ||
GB60/005,371 | 1996-03-18 | ||
PCT/CA1996/000682 WO1997014691A1 (en) | 1995-10-13 | 1996-10-09 | (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000366579A Division JP4068802B2 (ja) | 1995-10-13 | 2000-12-01 | Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11500146A true JPH11500146A (ja) | 1999-01-06 |
JP3337476B2 JP3337476B2 (ja) | 2002-10-21 |
Family
ID=27451401
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51537197A Expired - Lifetime JP3337476B2 (ja) | 1995-10-13 | 1996-10-09 | Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類 |
JP2000366579A Expired - Lifetime JP4068802B2 (ja) | 1995-10-13 | 2000-12-01 | Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000366579A Expired - Lifetime JP4068802B2 (ja) | 1995-10-13 | 2000-12-01 | Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類 |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP0863891B1 (ja) |
JP (2) | JP3337476B2 (ja) |
KR (1) | KR100354940B1 (ja) |
CN (1) | CN1203066C (ja) |
AT (1) | ATE229515T1 (ja) |
AU (1) | AU703871B2 (ja) |
BG (1) | BG63391B1 (ja) |
BR (1) | BR9611015A (ja) |
CA (1) | CA2233178C (ja) |
CO (1) | CO4770965A1 (ja) |
CZ (1) | CZ295764B6 (ja) |
DE (2) | DE69625374T2 (ja) |
DK (1) | DK0863891T3 (ja) |
DZ (1) | DZ2103A1 (ja) |
EA (1) | EA000795B1 (ja) |
EE (1) | EE03969B1 (ja) |
ES (1) | ES2187675T3 (ja) |
HK (1) | HK1016980A1 (ja) |
HR (1) | HRP960458B1 (ja) |
HU (1) | HU222785B1 (ja) |
IL (1) | IL123699A (ja) |
IS (1) | IS2148B (ja) |
LU (1) | LU91145I2 (ja) |
MX (1) | MX9802836A (ja) |
MY (1) | MY141773A (ja) |
NL (1) | NL300175I2 (ja) |
NO (1) | NO321042B1 (ja) |
NZ (1) | NZ319090A (ja) |
PE (1) | PE17198A1 (ja) |
PL (1) | PL188918B1 (ja) |
PT (1) | PT863891E (ja) |
RO (1) | RO119884B1 (ja) |
RS (1) | RS49885B (ja) |
SA (1) | SA96170405B1 (ja) |
SK (1) | SK282639B6 (ja) |
TR (1) | TR199800585T2 (ja) |
TW (1) | TW426679B (ja) |
UA (1) | UA57002C2 (ja) |
WO (1) | WO1997014691A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511443A (ja) * | 1999-10-08 | 2003-03-25 | メリアル | 3−(シクロプロピルメトキシ)−4−[4−(メチルスルホニル)フェニル]−5,5−ジメチル−5h−フラン−2−オンの多型型b |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515014B2 (en) | 1995-06-02 | 2003-02-04 | G. D. Searle & Co. | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
CA2244897C (en) | 1996-03-05 | 2006-04-11 | Zeneca Limited | 4-anilinoquinazoline derivatives |
US5883267A (en) * | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
ATE244232T1 (de) * | 1997-03-14 | 2003-07-15 | Merck Frosst Canada Inc | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer |
US6071954A (en) * | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
WO1999015513A1 (en) * | 1997-09-24 | 1999-04-01 | Merck & Co., Inc. | Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of cox-2 |
FR2770131A1 (fr) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
GB2330833A (en) * | 1997-10-29 | 1999-05-05 | Merck & Co Inc | PREPARATION OF 4-(4-Methylsulfonylphenyl)-2-furanones USEFUL AS COX-2 INHIBITORS |
CA2307853A1 (en) * | 1997-10-30 | 1999-05-14 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors |
US6133292A (en) * | 1997-10-30 | 2000-10-17 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors |
FR2771005B1 (fr) * | 1997-11-18 | 2002-06-07 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
EP1061908A4 (en) * | 1998-03-13 | 2007-01-24 | Merck & Co Inc | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY MIXING SYNDROME AND ASSOCIATED CONDITIONS |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
ES2140354B1 (es) * | 1998-08-03 | 2000-11-01 | S A L V A T Lab Sa | Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2. |
EP1124798A4 (en) * | 1998-10-27 | 2002-08-28 | Merck & Co Inc | SYNTHESIS OF METHYLTHIOPHENYL HYDROXYKETONES |
US6492416B1 (en) * | 1999-04-14 | 2002-12-10 | Pacific Corporation | 4,5-diaryl-3(2H)-furanone derivatives as cyclooxygenase-2 inhibitors |
FR2799462B1 (fr) | 1999-10-08 | 2004-05-28 | Merial Sas | Procede de preparation d'inhibiteurs cox-2 |
SI1676845T1 (sl) | 1999-11-05 | 2008-10-31 | Astrazeneca Ab | Novi kinazolinski derivati |
PT1104758E (pt) | 1999-12-03 | 2003-12-31 | Pfizer Prod Inc | Derivados de acetileno como agentes anti-inflamatorios/analgesicos |
EP1104759B1 (en) | 1999-12-03 | 2003-10-22 | Pfizer Products Inc. | Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
KR20020058074A (ko) | 1999-12-03 | 2002-07-12 | 데이비드 존 우드 | 소염진통제로서의 헤테로시클로-알킬술포닐 피라졸 유도체 |
DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
AU3653301A (en) * | 2000-01-28 | 2001-08-07 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
ES2241964T3 (es) | 2001-07-05 | 2005-11-01 | Pfizer Products Inc. | Heterocicloalquilsulfufonilpirazoles como agentes antiinflamatorios/abnalgesicos. |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
WO2003037336A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
CN1309717C (zh) * | 2003-06-03 | 2007-04-11 | 李小虎 | 4-芳基-5h-噻吩-2-酮衍生物、其制法和用途 |
WO2006041855A2 (en) | 2004-10-04 | 2006-04-20 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
ATE424386T1 (de) | 2004-12-23 | 2009-03-15 | Glaxo Group Ltd | Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten |
US20090018091A1 (en) | 2005-08-02 | 2009-01-15 | Nitromed, Inc. | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use |
BRPI0616552A2 (pt) * | 2005-08-19 | 2011-06-21 | Emisphere Tech Inc | composto de ciclopropila, composição para liberação de ativos, forma unitária de dosagem, método para administrar um agente biologicamente ativo e método para preparar uma composição |
AU2007243765A1 (en) | 2006-03-29 | 2007-11-08 | Nicox S.A. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
EP1878717A1 (en) | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
EP2062880A1 (en) * | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
WO2012004604A1 (en) | 2010-07-09 | 2012-01-12 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
US8933132B2 (en) | 2011-01-19 | 2015-01-13 | Convergence Pharmaceuticals Limited | Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
CN110818660B (zh) | 2012-09-21 | 2023-09-12 | 罗得岛医院 | 用于治疗癌症的β-羟化酶抑制剂 |
GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
CN104803956A (zh) * | 2015-03-06 | 2015-07-29 | 江苏天和制药有限公司 | 非罗考昔的一种合成方法 |
EP3292213A1 (en) | 2015-05-04 | 2018-03-14 | Academisch Medisch Centrum | Biomarkers for the detection of aspirin insensitivity |
WO2018188763A1 (en) | 2017-04-14 | 2018-10-18 | Cosma S.P.A. | New process for the synthesis of firocoxib |
CN108178724B (zh) * | 2017-12-22 | 2020-09-11 | 四川大学 | 化合物的制备方法 |
CN110240537B (zh) * | 2019-05-22 | 2022-06-21 | 成都阿奇生物医药科技有限公司 | 一种茚氧乙酸类化合物及其制备方法和用途 |
CN110452199B (zh) * | 2019-09-03 | 2021-03-30 | 山东鲁抗舍里乐药业有限公司 | 一种非罗考昔的制备方法 |
CN110452198B (zh) * | 2019-09-03 | 2021-03-26 | 山东鲁抗舍里乐药业有限公司 | 一种非罗考昔的制备方法 |
DE102019214427A1 (de) | 2019-09-23 | 2021-03-25 | Multivac Marking & Inspection Gmbh & Co. Kg | Etikettierer mit Montageeinrichtung für Andrückelement |
CN110746390B (zh) * | 2019-11-14 | 2022-12-30 | 中国科学技术大学 | 制备5-甲酰基-2-呋喃甲酸酯的方法 |
IL305573A (en) | 2021-03-15 | 2023-10-01 | Saul Yedgar | Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases |
CN113248458B (zh) * | 2021-05-27 | 2022-09-27 | 陕西省煤田地质集团有限公司 | 一种α-羰基酰胺化合物的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
AU702591B2 (en) * | 1994-12-21 | 1999-02-25 | Merck Frosst Canada Ltd. | Diaryl-2-(5H)-furanones as cox-2 inhibitors |
-
1996
- 1996-09-10 UA UA98041875A patent/UA57002C2/uk unknown
- 1996-10-07 HR HR960458A patent/HRP960458B1/xx not_active IP Right Cessation
- 1996-10-08 MY MYPI96004167A patent/MY141773A/en unknown
- 1996-10-09 KR KR10-1998-0702755A patent/KR100354940B1/ko not_active IP Right Cessation
- 1996-10-09 PT PT96932417T patent/PT863891E/pt unknown
- 1996-10-09 IL IL12369996A patent/IL123699A/en not_active IP Right Cessation
- 1996-10-09 HU HU9802506A patent/HU222785B1/hu active Protection Beyond IP Right Term
- 1996-10-09 SK SK450-98A patent/SK282639B6/sk not_active IP Right Cessation
- 1996-10-09 DK DK96932417T patent/DK0863891T3/da active
- 1996-10-09 CZ CZ19981101A patent/CZ295764B6/cs not_active IP Right Cessation
- 1996-10-09 DE DE69625374T patent/DE69625374T2/de not_active Expired - Lifetime
- 1996-10-09 CN CNB961976098A patent/CN1203066C/zh not_active Expired - Lifetime
- 1996-10-09 AT AT96932417T patent/ATE229515T1/de active
- 1996-10-09 TR TR1998/00585T patent/TR199800585T2/xx unknown
- 1996-10-09 RO RO98-00856A patent/RO119884B1/ro unknown
- 1996-10-09 AU AU71236/96A patent/AU703871B2/en not_active Expired
- 1996-10-09 EE EE9800080A patent/EE03969B1/xx active Protection Beyond IP Right Term
- 1996-10-09 DE DE200512000010 patent/DE122005000010I2/de active Active
- 1996-10-09 PE PE1996000715A patent/PE17198A1/es not_active IP Right Cessation
- 1996-10-09 DZ DZ960147A patent/DZ2103A1/fr active
- 1996-10-09 BR BR9611015-5A patent/BR9611015A/pt not_active IP Right Cessation
- 1996-10-09 WO PCT/CA1996/000682 patent/WO1997014691A1/en active IP Right Grant
- 1996-10-09 JP JP51537197A patent/JP3337476B2/ja not_active Expired - Lifetime
- 1996-10-09 PL PL96326203A patent/PL188918B1/pl unknown
- 1996-10-09 EA EA199800290A patent/EA000795B1/ru not_active IP Right Cessation
- 1996-10-09 EP EP96932417A patent/EP0863891B1/en not_active Expired - Lifetime
- 1996-10-09 NZ NZ319090A patent/NZ319090A/xx not_active IP Right Cessation
- 1996-10-09 CA CA002233178A patent/CA2233178C/en not_active Expired - Lifetime
- 1996-10-09 ES ES96932417T patent/ES2187675T3/es not_active Expired - Lifetime
- 1996-10-10 RS YUP-548/96A patent/RS49885B/sr unknown
- 1996-10-10 CO CO96053995A patent/CO4770965A1/es unknown
- 1996-10-12 TW TW085112463A patent/TW426679B/zh not_active IP Right Cessation
- 1996-10-30 SA SA96170405A patent/SA96170405B1/ar unknown
-
1998
- 1998-03-20 IS IS4695A patent/IS2148B/is unknown
- 1998-04-08 MX MX9802836A patent/MX9802836A/es unknown
- 1998-04-08 NO NO19981628A patent/NO321042B1/no not_active IP Right Cessation
- 1998-05-04 BG BG102425A patent/BG63391B1/bg unknown
-
1999
- 1999-05-07 HK HK99102061A patent/HK1016980A1/xx not_active IP Right Cessation
-
2000
- 2000-12-01 JP JP2000366579A patent/JP4068802B2/ja not_active Expired - Lifetime
-
2005
- 2005-02-14 NL NL300175C patent/NL300175I2/nl unknown
- 2005-03-09 LU LU91145C patent/LU91145I2/fr unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511443A (ja) * | 1999-10-08 | 2003-03-25 | メリアル | 3−(シクロプロピルメトキシ)−4−[4−(メチルスルホニル)フェニル]−5,5−ジメチル−5h−フラン−2−オンの多型型b |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4068802B2 (ja) | Cox−2インヒビターとしての(メチルスルホニル)フェニル−2−(5h)−フラノン類 | |
US6169188B1 (en) | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | |
US5698584A (en) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors | |
US5981576A (en) | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | |
US6057319A (en) | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors | |
US5925631A (en) | Alkylated styrenes as prodrugs to COX-2 inhibitors | |
EP0904269B1 (en) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors | |
US5521213A (en) | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 | |
JP4004541B2 (ja) | Cox―2阻害剤のプロドラッグとしてのアルキル化スチレン | |
JP2004505943A (ja) | シクロオキシゲナーゼ−2阻害薬としてのピロン類 | |
AU741790B2 (en) | Diaryl-5-alkyl-5-methyl-2(5H)-furanones as selective cyclooxygenase-2 inhibitors | |
AU711902C (en) | 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070809 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080809 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080809 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090809 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090809 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100809 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100809 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110809 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110809 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120809 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130809 Year of fee payment: 11 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |